TW_GPS_D的个人主页 - 老虎社区

TW_GPS_D

TW_GPS_D

True Wealth GPS Daddy

IP属地：未知

24关注

28粉丝

1主题

0勋章

2021-08-31

With 80% Population Vaccinated. I Wonder Why SG STI ETF is going down?Will Continue To Collect.

2021-11-22

👍🏻$SINGAPORE PRESS HLDGS LTD(T39.SI)$Don’t expect much price movement on or after Ex Div date. If you sell below $3.60, are you making a gain from dividend or are you cutting losses?

抱歉，原内容已删除

2021-10-20

Patient For Profit

$STI ETF(ES3.SI)$Most people don’t make profit because they are too quick to sell. You need to and your homework and believe in your work. Buy when the price drop and wait paitiently for the price to reach your selling range before you take profit. Talk is simple. True Wealth G.P.S Daddy walk his talk.

Patient For Profit

2021-09-16

Up or down, they will always have a story to tell.

Wall Street gains as crude price surge, strong economic data prompt broad rally

2021-09-18

Their Vote,Your Life.

FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations

2021-11-15

Did her dumping value add to the funds?

Cathie Wood Goes Dumpster Diving: 3 Stocks She Just Bought

2021-09-22

All you want is $$$. Here that it and leave me alone!

Facebook overpaid FTC fine as 'quid pro quo' to protect Zuckerberg from liability, shareholders claim

2021-12-14

If Bitcoin is Gold.What is Dogcoin?It seem now a month or two, a new coin is born. If now and then a new coin can be born, how valuable can your coin be in the future?

Bitcoin is About 90% Mined Out

2021-11-11

It a risk. But will be interesting if Keppel don’t follow through their offer. Since 2.351 is final offer. Anyone who really want SHP only need to offer 2.352 or higher to beat Keppel. =\\=There is still some profit to be made. Not forgetting up coming div of, $0.03?

Hot stocks: SPH, SPH Reit, Keppel, Keppel Reit see active trading after Keppel's counter offer for SPH

2021-11-11

Buy$SINGAPORE PRESS HLDGS LTD(T39.SI)$$SINGAPORE PRESS HLDGS LTD(T39.SI)$Current Price Is Lower Than The Offer Price

2021-09-19

Trading is perhaps the 8th way men live without working in the World.

7 ways men live without working in America

2021-09-21

Fund House Are The One Who Can Move And Make The Market.

抱歉，原内容已删除

2021-10-28

Willing Buyer, Willing Seller. They Both Will Think They Got A Good Deal. But Only Their Result Will Tell.

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3581689230768222","uuid":"3581689230768222","gmtCreate":1618802384961,"gmtModify":1639904681585,"name":"TW_GPS_D","pinyin":"twgpsdtwgpsd","introduction":"","introductionEn":null,"signature":"True Wealth GPS Daddy","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":28,"headSize":24,"tweetSize":13,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.44%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":607036402,"gmtCreate":1639455056578,"gmtModify":1639458879625,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"If Bitcoin is Gold.What is Dogcoin?It seem now a month or two, a new coin is born.&nbsp;If now and then a new coin can be born, how valuable can your coin be in the future?","listText":"If Bitcoin is Gold.What is Dogcoin?It seem now a month or two, a new coin is born.&nbsp;If now and then a new coin can be born, how valuable can your coin be in the future?","text":"If Bitcoin is Gold.What is Dogcoin?It seem now a month or two, a new coin is born. If now and then a new coin can be born, how valuable can your coin be in the future?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/607036402","repostId":"1134867438","repostType":4,"isVote":1,"tweetType":1,"viewCount":778,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872507055,"gmtCreate":1637544086291,"gmtModify":1637544086527,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"👍🏻<a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a>Don’t expect much price movement on or after Ex Div date.&nbsp;If you sell below $3.60, are you making a gain from dividend or are you cutting losses?","listText":"👍🏻<a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a>Don’t expect much price movement on or after Ex Div date.&nbsp;If you sell below $3.60, are you making a gain from dividend or are you cutting losses?","text":"👍🏻$SINGAPORE PRESS HLDGS LTD(T39.SI)$Don’t expect much price movement on or after Ex Div date. If you sell below $3.60, are you making a gain from dividend or are you cutting losses?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/872507055","repostId":"1174499408","repostType":4,"isVote":1,"tweetType":1,"viewCount":1109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873521275,"gmtCreate":1636964532977,"gmtModify":1636964533511,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"Did her dumping value add to the funds?","listText":"Did her dumping value add to the funds?","text":"Did her dumping value add to the funds?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873521275","repostId":"2183046479","repostType":4,"repost":{"id":"2183046479","kind":"highlight","pubTimestamp":1636962804,"share":"https://www.laohu8.com/m/news/2183046479?lang=&edition=full","pubTime":"2021-11-15 15:53","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2183046479","media":"Motley Fool","summary":"A trio of stocks you might consider adding to your portfolio.","content":"<p>Cathie Wood runs one(AONE.U) of the most popular tech stock funds, the <b>ARK Innovation Fund </b>(NYSEMKT:ARKK), with more than $19 billion under management. This fund is not only popular, but it is also soundly beating the <b>S&amp;P 500</b> with a five-year return of 39% annually (as of Sept. 30).&nbsp;Cathie Wood runs this fund and seven other tech-focused funds that are popular with growth investors. One of the things that makes her a popular investor to follow is that all the buys and sells from these funds are published daily.</p>\n<p>Since she has a history of picking high-tech stocks at good prices, we asked three Motley Fool contributors to highlight one company that her funds have purchased recently that investors should consider adding to their portfolio.</p>\n<p>They came up with <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> </b>(NASDAQ:FB), <b>Palantir</b> (NYSE:PLTR), and <b>Twilio</b> (NYSE:TWLO).</p>\n<h2>Meta Platforms: The company formerly known as Facebook</h2>\n<p><b>Danny Vena (Meta Platforms): </b>The <b><a href=\"https://laohu8.com/S/ARKF\">ARK Fintech Innovation ETF</a></b> has made some bold moves lately, no doubt spurred on by Cathie Wood's vision of the future. One of the biggest purchases over the past week is the addition of a big chunk of Meta Platforms, the company formerly known as Facebook.</p>\n<p>Over the past week, the fund has stockpiled more than 100,000 shares of Meta, worth more than $33 million (as of this writing). Perhaps more importantly, ARK Fintech Innovation already had a substantial stake in Meta, now equal to a roughly 3% position, and valued at nearly $103 million -- making it the fund's 11th largest position.</p>\n<p>Meta has been working to debut its long-awaited digital currency dubbed Diem, formerly known as Libra. The company is a founding member of the Diem Association, which underpins the upcoming cryptocurrency.&nbsp;Diem is a blockchain-based payment system that was designed from the ground up with payments in mind, focusing on \"consumer safety, financial stability, and combating financial crime.\"</p>\n<p>Additionally, just last month, Meta launched a pilot of Novi -- its cryptocurrency wallet -- to a small number of users in the U.S. and Guatemala.</p>\n<p>Given Wood's early adoption and bullish track record regarding <b>Bitcoin</b>, it's little wonder the rock star investor might place a similar bet on a Meta-backed cryptocurrency and digital wallet. But those fintech aspirations notwithstanding, there are plenty of other reasons to be bullish on Meta.</p>\n<p>Let's not forget that Facebook is one of the most recognized companies on the planet. For the third quarter, Facebook reported 1.93 billion daily active users (DAUs), up 6% year over year, and 2.91 billion monthly active users (MAUs). When you expand that to include the company's other platforms (Instagram, WhatsApp, and Messenger) that rises to 2.81 billion DAUs and 3.58 billion MAUs.</p>\n<p>That many users creates a powerful network effect for the social media baron, helping Meta generate significant advertising revenue to support its moonshots. In the third quarter, revenue of $29 billion grew 35% year over year -- even as the company dealt with privacy reforms rolled out by <b>Apple</b>, which made it more difficult to measure the success of advertising campaigns across devices using iOS. Meta also generated more than $9.1 billion in net income and $9.5 billion in free cash flow.</p>\n<p>Even as the company faces regulatory challenges, Meta is preparing for the metaverse, a digital realm online where users play, work, and shop. Meta describes this as \"the next evolution of social connection ... [where] you'll be able to socialize, learn, collaborate and play in ways that go beyond what's possible today.\"</p>\n<p>Meta sees the metaverse as its next big growth driver, as well as a way to retain young, tech savvy users. The company has a head start in the areas of augmented reality (AR) and virtual-reality, which will likely be key components in its broader strategy.</p>\n<p>It also doesn't hurt that the stock is on sale at a 15% discount to recent highs.</p>\n<h2>Palantir: Wood continues adding shares to this insight seeker</h2>\n<p><b>Will Healy</b> <b>(Palantir): </b>Palantir stands out from other data companies in that it specializes in delivering insights. The company works with national security and law enforcement organizations through its Gotham software, functionality that has everyone talking about Palantir stock.</p>\n<p>Moreover, the company has also developed a product for the commercial space, called Foundry, which currently drives the company's fastest growth.</p>\n<p>Seeing the potential of these products, Wood has accumulated Palantir shares in the ARK Innovation Fund since February, buying multiple lots with only one sale in September. This has taken the total in that fund to more than 24 million shares, a 2.8% weighting. Wood has added Palantir shares less aggressively to the <b>ARK Industrial Innovation ETF</b>. Nonetheless, more than 1.1 million Palantir shares make up about 1% of this fund.</p>\n<p>Palantir reported strong numbers in its third-quarter 2021 earnings report. Third-quarter revenue of $392 million surged 36% from year-ago levels. This led to an adjusted net income of $82 million. Palantir also raised fourth-quarter guidance, and predicted the $418 million in revenue will rise 30% year over year if that number holds.</p>\n<p>Nonetheless, the stock dropped 9% in Tuesday trading as the company forecast an adjusted operating margin of 22% for Q4. Analysts had expected 24%. Moreover, a government document indicated that U.S. Immigration and Customs Enforcement (ICE) might replace Palantir's system with a competing product, though a recent U.S. Army contract could mitigate that loss.</p>\n<p>Additionally, while Wood bought just under 1 million shares between the two funds on that day, the stock fell an additional 7% on Wednesday. With that move, Palantir stock wipes out all of its 2021 gains and has fallen 4% in 2021 as of the time of this writing. Also, despite that drop, Palantir trades at a price-to-sales (P/S) ratio of 27, well above the average S&amp;P 500 stock, which sells at just over three times sales.</p>\n<p>With its data insight capabilities, Palantir's massive revenue growth should continue. However, given the high sales multiple and the stock falling on a mostly favorable earnings report, investors may not want to follow Wood's lead in the near term.</p>\n<h2>Twilio: Expanding its mission</h2>\n<p><b>Brian Withers (Twilio): </b>Twilio announced earnings on Oct. 28, and the stock took a 17% haircut the next day. Since then, Cathie Wood's ARK funds snapped up over 415,000 shares of the stock representing about $122 million. These buys moved this customer communication platform specialist to the 12th largest holding across its funds. Let take a look at why she might be buying massive quantities of this tech company, which appears to be on sale.</p>\n<p>First, let's look at the quarterly results and why investors may have been spooked. The top line grew at a massive 65% year over year, but subtracting the contributions for the Zipwhip and Segment.io acquisitions, the year-over-year growth drops to 38%. This is a deceleration from the last four quarters of organic year-over-year growth that were between 47% and 54%. This slowdown was one reason for the stock sell-off, the other was likely the growing losses. Expenses increased faster than revenue this quarter and the company more than doubled its operating loss year over year.</p>\n<table>\n <thead>\n  <tr>\n   <th><p>Metrics</p></th>\n   <th><p>Q3 2020</p></th>\n   <th><p>Q2 2021</p></th>\n   <th><p>Q3 2021</p></th>\n   <th><p>Change (QOQ)</p></th>\n   <th><p>Change (YOY)</p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td><p>Revenue</p></td>\n   <td><p>$448 million</p></td>\n   <td><p>$669 million</p></td>\n   <td><p>$740 million</p></td>\n   <td><p>11%</p></td>\n   <td><p>65%</p></td>\n  </tr>\n  <tr>\n   <td><p>Organic revenue</p></td>\n   <td><p>$438 million</p></td>\n   <td><p>$590 million</p></td>\n   <td><p>$606 million</p></td>\n   <td><p>3%</p></td>\n   <td><p>38%</p></td>\n  </tr>\n  <tr>\n   <td><p>Operating income (loss)</p></td>\n   <td><p>($112 million)</p></td>\n   <td><p>($227 million)</p></td>\n   <td><p>($232 million)</p></td>\n   <td><p>n/a</p></td>\n   <td><p>n/a</p></td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Company earnings release. QOQ = quarter over quarter. YOY = year over year.</p>\n<p>But one quarter doesn't make a trend and this company's got a lot up its sleeve. It just announced its Twilio Engage platform which takes advantage of the integration of Segment.io's customer data platform and Twilio's core messaging services. This new product will enable businesses to personalize messages based on customer behaviors and will make the messages customers receive even more relevant to their needs.</p>\n<p>Lastly, the company has updated its mission. For the last 13 years, the mission has been \"Fuel the Future of Communications.\" Today the mission is broader, focusing on its core user, the software developer. It is to \"Unlock the Imagination of Builders.\" This may not make any impact this quarter or even in the coming year. But over time, this allows the company to expand beyond just its communication products.</p>\n<p>With the stock more than 30% off its high, it could be a good time to jump in and pick up some shares yourself. You probably won't be buying in the amount that the ARK funds have, but even if you just add a few shares today, in five years, it's likely you'll be very happy you did.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 15:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/14/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood runs one(AONE.U) of the most popular tech stock funds, the ARK Innovation Fund (NYSEMKT:ARKK), with more than $19 billion under management. This fund is not only popular, but it is also ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/14/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","PLTR":"Palantir Technologies Inc."},"source_url":"https://www.fool.com/investing/2021/11/14/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183046479","content_text":"Cathie Wood runs one(AONE.U) of the most popular tech stock funds, the ARK Innovation Fund (NYSEMKT:ARKK), with more than $19 billion under management. This fund is not only popular, but it is also soundly beating the S&P 500 with a five-year return of 39% annually (as of Sept. 30). Cathie Wood runs this fund and seven other tech-focused funds that are popular with growth investors. One of the things that makes her a popular investor to follow is that all the buys and sells from these funds are published daily.\nSince she has a history of picking high-tech stocks at good prices, we asked three Motley Fool contributors to highlight one company that her funds have purchased recently that investors should consider adding to their portfolio.\nThey came up with Meta Platforms (NASDAQ:FB), Palantir (NYSE:PLTR), and Twilio (NYSE:TWLO).\nMeta Platforms: The company formerly known as Facebook\nDanny Vena (Meta Platforms): The ARK Fintech Innovation ETF has made some bold moves lately, no doubt spurred on by Cathie Wood's vision of the future. One of the biggest purchases over the past week is the addition of a big chunk of Meta Platforms, the company formerly known as Facebook.\nOver the past week, the fund has stockpiled more than 100,000 shares of Meta, worth more than $33 million (as of this writing). Perhaps more importantly, ARK Fintech Innovation already had a substantial stake in Meta, now equal to a roughly 3% position, and valued at nearly $103 million -- making it the fund's 11th largest position.\nMeta has been working to debut its long-awaited digital currency dubbed Diem, formerly known as Libra. The company is a founding member of the Diem Association, which underpins the upcoming cryptocurrency. Diem is a blockchain-based payment system that was designed from the ground up with payments in mind, focusing on \"consumer safety, financial stability, and combating financial crime.\"\nAdditionally, just last month, Meta launched a pilot of Novi -- its cryptocurrency wallet -- to a small number of users in the U.S. and Guatemala.\nGiven Wood's early adoption and bullish track record regarding Bitcoin, it's little wonder the rock star investor might place a similar bet on a Meta-backed cryptocurrency and digital wallet. But those fintech aspirations notwithstanding, there are plenty of other reasons to be bullish on Meta.\nLet's not forget that Facebook is one of the most recognized companies on the planet. For the third quarter, Facebook reported 1.93 billion daily active users (DAUs), up 6% year over year, and 2.91 billion monthly active users (MAUs). When you expand that to include the company's other platforms (Instagram, WhatsApp, and Messenger) that rises to 2.81 billion DAUs and 3.58 billion MAUs.\nThat many users creates a powerful network effect for the social media baron, helping Meta generate significant advertising revenue to support its moonshots. In the third quarter, revenue of $29 billion grew 35% year over year -- even as the company dealt with privacy reforms rolled out by Apple, which made it more difficult to measure the success of advertising campaigns across devices using iOS. Meta also generated more than $9.1 billion in net income and $9.5 billion in free cash flow.\nEven as the company faces regulatory challenges, Meta is preparing for the metaverse, a digital realm online where users play, work, and shop. Meta describes this as \"the next evolution of social connection ... [where] you'll be able to socialize, learn, collaborate and play in ways that go beyond what's possible today.\"\nMeta sees the metaverse as its next big growth driver, as well as a way to retain young, tech savvy users. The company has a head start in the areas of augmented reality (AR) and virtual-reality, which will likely be key components in its broader strategy.\nIt also doesn't hurt that the stock is on sale at a 15% discount to recent highs.\nPalantir: Wood continues adding shares to this insight seeker\nWill Healy (Palantir): Palantir stands out from other data companies in that it specializes in delivering insights. The company works with national security and law enforcement organizations through its Gotham software, functionality that has everyone talking about Palantir stock.\nMoreover, the company has also developed a product for the commercial space, called Foundry, which currently drives the company's fastest growth.\nSeeing the potential of these products, Wood has accumulated Palantir shares in the ARK Innovation Fund since February, buying multiple lots with only one sale in September. This has taken the total in that fund to more than 24 million shares, a 2.8% weighting. Wood has added Palantir shares less aggressively to the ARK Industrial Innovation ETF. Nonetheless, more than 1.1 million Palantir shares make up about 1% of this fund.\nPalantir reported strong numbers in its third-quarter 2021 earnings report. Third-quarter revenue of $392 million surged 36% from year-ago levels. This led to an adjusted net income of $82 million. Palantir also raised fourth-quarter guidance, and predicted the $418 million in revenue will rise 30% year over year if that number holds.\nNonetheless, the stock dropped 9% in Tuesday trading as the company forecast an adjusted operating margin of 22% for Q4. Analysts had expected 24%. Moreover, a government document indicated that U.S. Immigration and Customs Enforcement (ICE) might replace Palantir's system with a competing product, though a recent U.S. Army contract could mitigate that loss.\nAdditionally, while Wood bought just under 1 million shares between the two funds on that day, the stock fell an additional 7% on Wednesday. With that move, Palantir stock wipes out all of its 2021 gains and has fallen 4% in 2021 as of the time of this writing. Also, despite that drop, Palantir trades at a price-to-sales (P/S) ratio of 27, well above the average S&P 500 stock, which sells at just over three times sales.\nWith its data insight capabilities, Palantir's massive revenue growth should continue. However, given the high sales multiple and the stock falling on a mostly favorable earnings report, investors may not want to follow Wood's lead in the near term.\nTwilio: Expanding its mission\nBrian Withers (Twilio): Twilio announced earnings on Oct. 28, and the stock took a 17% haircut the next day. Since then, Cathie Wood's ARK funds snapped up over 415,000 shares of the stock representing about $122 million. These buys moved this customer communication platform specialist to the 12th largest holding across its funds. Let take a look at why she might be buying massive quantities of this tech company, which appears to be on sale.\nFirst, let's look at the quarterly results and why investors may have been spooked. The top line grew at a massive 65% year over year, but subtracting the contributions for the Zipwhip and Segment.io acquisitions, the year-over-year growth drops to 38%. This is a deceleration from the last four quarters of organic year-over-year growth that were between 47% and 54%. This slowdown was one reason for the stock sell-off, the other was likely the growing losses. Expenses increased faster than revenue this quarter and the company more than doubled its operating loss year over year.\n\n\n\nMetrics\nQ3 2020\nQ2 2021\nQ3 2021\nChange (QOQ)\nChange (YOY)\n\n\n\n\nRevenue\n$448 million\n$669 million\n$740 million\n11%\n65%\n\n\nOrganic revenue\n$438 million\n$590 million\n$606 million\n3%\n38%\n\n\nOperating income (loss)\n($112 million)\n($227 million)\n($232 million)\nn/a\nn/a\n\n\n\nData source: Company earnings release. QOQ = quarter over quarter. YOY = year over year.\nBut one quarter doesn't make a trend and this company's got a lot up its sleeve. It just announced its Twilio Engage platform which takes advantage of the integration of Segment.io's customer data platform and Twilio's core messaging services. This new product will enable businesses to personalize messages based on customer behaviors and will make the messages customers receive even more relevant to their needs.\nLastly, the company has updated its mission. For the last 13 years, the mission has been \"Fuel the Future of Communications.\" Today the mission is broader, focusing on its core user, the software developer. It is to \"Unlock the Imagination of Builders.\" This may not make any impact this quarter or even in the coming year. But over time, this allows the company to expand beyond just its communication products.\nWith the stock more than 30% off its high, it could be a good time to jump in and pick up some shares yourself. You probably won't be buying in the amount that the ARK funds have, but even if you just add a few shares today, in five years, it's likely you'll be very happy you did.","news_type":1},"isVote":1,"tweetType":1,"viewCount":808,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870810989,"gmtCreate":1636598902047,"gmtModify":1636598902187,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"It a risk.&nbsp;But will be interesting if Keppel don’t follow through their offer.&nbsp;Since 2.351 is final offer.&nbsp;Anyone who really want SHP only need to offer 2.352 or higher to beat Keppel.&nbsp;=\\\\=There is still some profit to be made.&nbsp;Not forgetting up coming div of,&nbsp;$0.03?","listText":"It a risk.&nbsp;But will be interesting if Keppel don’t follow through their offer.&nbsp;Since 2.351 is final offer.&nbsp;Anyone who really want SHP only need to offer 2.352 or higher to beat Keppel.&nbsp;=\\\\=There is still some profit to be made.&nbsp;Not forgetting up coming div of,&nbsp;$0.03?","text":"It a risk. But will be interesting if Keppel don’t follow through their offer. Since 2.351 is final offer. Anyone who really want SHP only need to offer 2.352 or higher to beat Keppel. =\\\\=There is still some profit to be made. Not forgetting up coming div of, $0.03?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/870810989","repostId":"1183617975","repostType":4,"isVote":1,"tweetType":1,"viewCount":1074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870895246,"gmtCreate":1636597966619,"gmtModify":1636597981085,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"Buy<a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a><a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a>Current Price Is Lower Than The Offer Price","listText":"Buy<a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a><a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a>Current Price Is Lower Than The Offer Price","text":"Buy$SINGAPORE PRESS HLDGS LTD(T39.SI)$$SINGAPORE PRESS HLDGS LTD(T39.SI)$Current Price Is Lower Than The Offer Price","images":[{"img":"https://static.tigerbbs.com/15ca968203cbfcc5b2b2ae4a2c1273ec","width":"1242","height":"2208"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/870895246","isVote":1,"tweetType":1,"viewCount":1143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":855702498,"gmtCreate":1635397167980,"gmtModify":1635397168121,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"Willing Buyer, Willing Seller.&nbsp;They Both Will Think They Got A Good Deal.&nbsp;But Only&nbsp;Their Result Will Tell.&nbsp;","listText":"Willing Buyer, Willing Seller.&nbsp;They Both Will Think They Got A Good Deal.&nbsp;But Only&nbsp;Their Result Will Tell.&nbsp;","text":"Willing Buyer, Willing Seller. They Both Will Think They Got A Good Deal. But Only Their Result Will Tell.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/855702498","repostId":"2178323712","repostType":4,"repost":{"id":"2178323712","kind":"news","pubTimestamp":1635390141,"share":"https://www.laohu8.com/m/news/2178323712?lang=&edition=full","pubTime":"2021-10-28 11:02","market":"us","language":"en","title":"Anti-Ark ETF Betting Against Cathie Wood Changes Its Name","url":"https://stock-news.laohu8.com/highlight/detail?id=2178323712","media":"Bloomberg","summary":"Short ARKK ETF will be the Tuttle Capital Short Innovation ETF\nWood’s flagship fund is down 4.7% thi","content":"<ul>\n <li>Short ARKK ETF will be the Tuttle Capital Short Innovation ETF</li>\n <li>Wood’s flagship fund is down 4.7% this year after 2020 surge</li>\n</ul>\n<p>A planned exchange-traded fund designed to take the other side of Cathie Wood’s trades has decided against name-dropping the Ark Investment Management founder.</p>\n<p>The not-yet-launched Short ARKK ETF will be changing its name to the Tuttle Capital Short Innovation ETF, though it’s keeping the ticker SARK, according to Tuttle Capital Management LLC chief executive Matt Tuttle. He declined to comment further on the reason behind the switch.</p>\n<p>Despite the name change, SARK will still seek to track the inverse performance of the $23 billion Ark Innovation ETF (ticker ARKK) -- the largest fund in Ark Investment Management’s lineup -- through swaps contracts, as described in a July filing with the Securities and Exchange Commission. The ETF will charge an operating expense of 0.75%, in line with ARKK’s management fee.</p>\n<p><img src=\"https://static.tigerbbs.com/2510aa91e6ffc439756e191ee6277b9b\" tg-width=\"1200\" tg-height=\"675\" width=\"100%\" height=\"auto\"></p>\n<p>After a blockbuster 150% gain in 2020 for the firm’s flagship fund, Wood’s hot hand has cooled as of late. ARKK has dropped 4.7% so far this year, dragged down by a series of misfired bets in biotech and stay-at-home companies. Additionally, Wood’s funds have been offloading shares of the Tesla Inc. -- ARKK’s top holding -- over the past several months amid the electric-vehicle maker’s 47% surge this year.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anti-Ark ETF Betting Against Cathie Wood Changes Its Name</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnti-Ark ETF Betting Against Cathie Wood Changes Its Name\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-10-27/anti-ark-etf-betting-against-cathie-wood-changes-its-name><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Short ARKK ETF will be the Tuttle Capital Short Innovation ETF\nWood’s flagship fund is down 4.7% this year after 2020 surge\n\nA planned exchange-traded fund designed to take the other side of Cathie ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-27/anti-ark-etf-betting-against-cathie-wood-changes-its-name\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","ARKK":"ARK Innovation ETF"},"source_url":"https://www.bloomberg.com/news/articles/2021-10-27/anti-ark-etf-betting-against-cathie-wood-changes-its-name","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178323712","content_text":"Short ARKK ETF will be the Tuttle Capital Short Innovation ETF\nWood’s flagship fund is down 4.7% this year after 2020 surge\n\nA planned exchange-traded fund designed to take the other side of Cathie Wood’s trades has decided against name-dropping the Ark Investment Management founder.\nThe not-yet-launched Short ARKK ETF will be changing its name to the Tuttle Capital Short Innovation ETF, though it’s keeping the ticker SARK, according to Tuttle Capital Management LLC chief executive Matt Tuttle. He declined to comment further on the reason behind the switch.\nDespite the name change, SARK will still seek to track the inverse performance of the $23 billion Ark Innovation ETF (ticker ARKK) -- the largest fund in Ark Investment Management’s lineup -- through swaps contracts, as described in a July filing with the Securities and Exchange Commission. The ETF will charge an operating expense of 0.75%, in line with ARKK’s management fee.\n\nAfter a blockbuster 150% gain in 2020 for the firm’s flagship fund, Wood’s hot hand has cooled as of late. ARKK has dropped 4.7% so far this year, dragged down by a series of misfired bets in biotech and stay-at-home companies. Additionally, Wood’s funds have been offloading shares of the Tesla Inc. -- ARKK’s top holding -- over the past several months amid the electric-vehicle maker’s 47% surge this year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":805,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859675674,"gmtCreate":1634695896769,"gmtModify":1634695897230,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"title":"Patient For Profit","htmlText":"<a href=\"https://laohu8.com/S/ES3.SI\">$STI ETF(ES3.SI)$</a>Most people don’t make profit because they are too quick to sell.&nbsp;You need to and your homework and believe in your work.&nbsp;Buy when the price drop and wait paitiently for the price to reach your selling range before you take profit.&nbsp;Talk is simple.&nbsp;True Wealth G.P.S Daddy walk his talk.&nbsp;","listText":"<a href=\"https://laohu8.com/S/ES3.SI\">$STI ETF(ES3.SI)$</a>Most people don’t make profit because they are too quick to sell.&nbsp;You need to and your homework and believe in your work.&nbsp;Buy when the price drop and wait paitiently for the price to reach your selling range before you take profit.&nbsp;Talk is simple.&nbsp;True Wealth G.P.S Daddy walk his talk.&nbsp;","text":"$STI ETF(ES3.SI)$Most people don’t make profit because they are too quick to sell. You need to and your homework and believe in your work. Buy when the price drop and wait paitiently for the price to reach your selling range before you take profit. Talk is simple. True Wealth G.P.S Daddy walk his talk.","images":[{"img":"https://static.tigerbbs.com/cf4f49424aa17e01e18e867bceb180b4","width":"1242","height":"2208"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/859675674","isVote":1,"tweetType":1,"viewCount":1036,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":869689576,"gmtCreate":1632279965995,"gmtModify":1632801518539,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"All you want is $$$. Here that it and leave me alone!","listText":"All you want is $$$. Here that it and leave me alone!","text":"All you want is $$$. Here that it and leave me alone!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/869689576","repostId":"2169658327","repostType":4,"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860729860,"gmtCreate":1632216291350,"gmtModify":1632802019601,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"Fund House Are The One Who Can Move And Make The Market.","listText":"Fund House Are The One Who Can Move And Make The Market.","text":"Fund House Are The One Who Can Move And Make The Market.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860729860","repostId":"1198860415","repostType":4,"repost":{"id":"1198860415","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1632215250,"share":"https://www.laohu8.com/m/news/1198860415?lang=&edition=full","pubTime":"2021-09-21 17:07","market":"us","language":"en","title":"Cathie Wood's Ark Raises Stakes In Crypto Plays Robinhood, Coinbase — And Other Keys Trades From Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1198860415","media":"Benzinga","summary":"Cathie Wood- led Ark Invest on Monday further raised its exposure in Robinhood MarketsInc(NASDAQ:HOO","content":"<p><b>Cathie Wood</b>-&nbsp;led&nbsp;<b>Ark Invest</b>&nbsp;on Monday further raised its exposure in&nbsp;<b>Robinhood</b>&nbsp;<b>MarketsInc</b>(NASDAQ:HOOD) on the dip.</p>\n<p>The popular money managing firm bought 404,020 shares — estimated to be worth $16.4 million in Robinhood — on the day shares of the company closed 3.96% lower at $40.70 a share.</p>\n<p>As per reports, Robinhood is&nbsp;testing a highly-anticipated featurethat would allow users the ability to transfer cryptocurrencies supported on the app like<b>Bitcoin</b>(CRYPTO: BTC),&nbsp;<b>Ethereum</b>(CRYPTO: ETH) and&nbsp;<b>Dogecoin</b>(CRYPTO: DOGE).</p>\n<p>The New York-based investment manager bought shares in Robinhood via the&nbsp;<b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a> </b>and the&nbsp;<b><a href=\"https://laohu8.com/S/ARKF\">ARK Fintech Innovation ETF</a></b>. Besides the two ETFs, the&nbsp;<b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b> too owns shares in the company.</p>\n<p>The three ETFs held a total of 8 million shares —worth $326 million — in Robinhood as of Monday’s trades.</p>\n<p>Here are some of the other key trades for Ark on Monday:</p>\n<p>Bought 96,251 shares — estimated to be worth $22.7 million — in&nbsp;<b>CoinbaseGlobalInc</b>. Shares of the cryptocurrency exchange closed 3.53% lower at $236.53 on Monday.</p>\n<ul>\n <li>Bought 54,479 shares — estimated to be worth $15.3 million — in&nbsp;<b><a href=\"https://laohu8.com/S/ZM\">Zoom</a></b>&nbsp;<b>Video</b>&nbsp;<b><a href=\"https://laohu8.com/S/JCS\">Communications</a></b>&nbsp;<b>Inc</b>. Shares of the video calling company closed 2.44% lower at $280.67.</li>\n <li>Sold 2,605 shares — estimated to be worth $8.74 — in&nbsp;<b><a href=\"https://laohu8.com/S/AMZN\">Amazon.com</a> Inc</b> the day shares of the e-commerce company closed 3.08% lower at $3,355.73.</li>\n <li>Sold 10,400 shares — estimated to be worth $2.2 million — in&nbsp;<b><a href=\"https://laohu8.com/S/NVDA\">NVIDIA Corp</a></b>. Shares of NVIDIA closed 3.59% lower at $211.13.</li>\n</ul>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood's Ark Raises Stakes In Crypto Plays Robinhood, Coinbase — And Other Keys Trades From Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood's Ark Raises Stakes In Crypto Plays Robinhood, Coinbase — And Other Keys Trades From Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-09-21 17:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Cathie Wood</b>-&nbsp;led&nbsp;<b>Ark Invest</b>&nbsp;on Monday further raised its exposure in&nbsp;<b>Robinhood</b>&nbsp;<b>MarketsInc</b>(NASDAQ:HOOD) on the dip.</p>\n<p>The popular money managing firm bought 404,020 shares — estimated to be worth $16.4 million in Robinhood — on the day shares of the company closed 3.96% lower at $40.70 a share.</p>\n<p>As per reports, Robinhood is&nbsp;testing a highly-anticipated featurethat would allow users the ability to transfer cryptocurrencies supported on the app like<b>Bitcoin</b>(CRYPTO: BTC),&nbsp;<b>Ethereum</b>(CRYPTO: ETH) and&nbsp;<b>Dogecoin</b>(CRYPTO: DOGE).</p>\n<p>The New York-based investment manager bought shares in Robinhood via the&nbsp;<b><a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a> </b>and the&nbsp;<b><a href=\"https://laohu8.com/S/ARKF\">ARK Fintech Innovation ETF</a></b>. Besides the two ETFs, the&nbsp;<b><a href=\"https://laohu8.com/S/ARKW\">ARK Next Generation Internet ETF</a></b> too owns shares in the company.</p>\n<p>The three ETFs held a total of 8 million shares —worth $326 million — in Robinhood as of Monday’s trades.</p>\n<p>Here are some of the other key trades for Ark on Monday:</p>\n<p>Bought 96,251 shares — estimated to be worth $22.7 million — in&nbsp;<b>CoinbaseGlobalInc</b>. Shares of the cryptocurrency exchange closed 3.53% lower at $236.53 on Monday.</p>\n<ul>\n <li>Bought 54,479 shares — estimated to be worth $15.3 million — in&nbsp;<b><a href=\"https://laohu8.com/S/ZM\">Zoom</a></b>&nbsp;<b>Video</b>&nbsp;<b><a href=\"https://laohu8.com/S/JCS\">Communications</a></b>&nbsp;<b>Inc</b>. Shares of the video calling company closed 2.44% lower at $280.67.</li>\n <li>Sold 2,605 shares — estimated to be worth $8.74 — in&nbsp;<b><a href=\"https://laohu8.com/S/AMZN\">Amazon.com</a> Inc</b> the day shares of the e-commerce company closed 3.08% lower at $3,355.73.</li>\n <li>Sold 10,400 shares — estimated to be worth $2.2 million — in&nbsp;<b><a href=\"https://laohu8.com/S/NVDA\">NVIDIA Corp</a></b>. Shares of NVIDIA closed 3.59% lower at $211.13.</li>\n</ul>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","ARKF":"ARK Fintech Innovation ETF","ARKW":"ARK Next Generation Internation ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198860415","content_text":"Cathie Wood- led Ark Invest on Monday further raised its exposure in Robinhood MarketsInc(NASDAQ:HOOD) on the dip.\nThe popular money managing firm bought 404,020 shares — estimated to be worth $16.4 million in Robinhood — on the day shares of the company closed 3.96% lower at $40.70 a share.\nAs per reports, Robinhood is testing a highly-anticipated featurethat would allow users the ability to transfer cryptocurrencies supported on the app likeBitcoin(CRYPTO: BTC), Ethereum(CRYPTO: ETH) and Dogecoin(CRYPTO: DOGE).\nThe New York-based investment manager bought shares in Robinhood via the ARK Innovation ETF and the ARK Fintech Innovation ETF. Besides the two ETFs, the ARK Next Generation Internet ETF too owns shares in the company.\nThe three ETFs held a total of 8 million shares —worth $326 million — in Robinhood as of Monday’s trades.\nHere are some of the other key trades for Ark on Monday:\nBought 96,251 shares — estimated to be worth $22.7 million — in CoinbaseGlobalInc. Shares of the cryptocurrency exchange closed 3.53% lower at $236.53 on Monday.\n\nBought 54,479 shares — estimated to be worth $15.3 million — in Zoom Video Communications Inc. Shares of the video calling company closed 2.44% lower at $280.67.\nSold 2,605 shares — estimated to be worth $8.74 — in Amazon.com Inc the day shares of the e-commerce company closed 3.08% lower at $3,355.73.\nSold 10,400 shares — estimated to be worth $2.2 million — in NVIDIA Corp. Shares of NVIDIA closed 3.59% lower at $211.13.","news_type":1},"isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887684315,"gmtCreate":1632027245537,"gmtModify":1632803234512,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"Trading is perhaps the 8th way men live without working in the World.","listText":"Trading is perhaps the 8th way men live without working in the World.","text":"Trading is perhaps the 8th way men live without working in the World.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/887684315","repostId":"1198486138","repostType":4,"repost":{"id":"1198486138","kind":"news","pubTimestamp":1632023224,"share":"https://www.laohu8.com/m/news/1198486138?lang=&edition=full","pubTime":"2021-09-19 11:47","market":"us","language":"en","title":"7 ways men live without working in America","url":"https://stock-news.laohu8.com/highlight/detail?id=1198486138","media":"Yahoo Finance","summary":"How do they live? What are they doing for money? ","content":"<p>Almost one-third of all working-age men in America aren’t doing diddly-squat. They don’t have a job, and they aren’t looking for one either. One-third of all working-age men. That’s almost 30 million people!</p>\n<p>How do they live? What are they doing for money? To me, this is one of the great mysteries of our time.</p>\n<p>I’m certainly not the first person to make note of this shocking statistic. You’ve heard people bemoaning this \"labor participation rate,\" which is simply the number of working-age men (usually counted as ages 16 to 64) not working or not looking for work, as a percentage of the overall labor force.</p>\n<p>It’s true that the pandemic, which of course produced a number of factors that made working more difficult never mind dangerous, pushed the labor participation rate to a record low. But the fact that millions of American males have not been working precedes COVID-19 by decades. In fact, the participation rate for men peaked at 87.4% in October 1949 and has been dropping steadily ever since. It now stands at 67.7%.</p>\n<p>As a business journalist for a good portion of those 70-plus years, I’ve looked at thousands of charts and graphs in my life, and I have to say this one is as jaw dropping as it is vexing:</p>\n<p><img src=\"https://static.tigerbbs.com/056158b8fa7157238c3d1521dd05c02e\" tg-width=\"705\" tg-height=\"259\" referrerpolicy=\"no-referrer\">Chart of the U.S. labor force participation rate for men over time, courtesy of the St. Louis Federal Reserve</p>\n<p>Economists, sociologists, politicians, and cable news pundits each have their pet factors to explain the groundswell of non-work. But after digging down here, I’ve concluded there are many different forces at play. That’s what I want to explore today, which is: how men can live in America without working.</p>\n<p>I’m not talking about why men have lost their jobs — factories closing, layoffs, automation, outsourcing jobs overseas, even perhaps women entering the workforce, (in fact, the participation rate by women over the same time period is way up). What I want to get at is how they’re living without holding a \"real\" job, and by that I mean doing work where one reports income to the IRS, pays taxes and Social Security, etc.</p>\n<p>It’s important to note that every man in this group has his own story. They range from mentally ill homeless men who desperately need our help, to the I’m-doing-just-fine-thank-you-very-much, retired early, and former Silicon Valley coder. And there are infinite scenarios in between those two extremes, including, for instance, the many men who have chosen to bestay-at-home dadswhile their spouses work.</p>\n<p>It’s also the case that some men in this group may be unemployed and not seeking work because they’ve given up looking just for now — perhaps waiting for COVID to abate — and will start the search again soon. Here too, society needs to help.</p>\n<p>Still, none of this explains decade after decade of falling male employment.</p>\n<p>To that end, here to my mind are seven ways men are living without working in America:</p>\n<p><b>-Unemployment insurance</b></p>\n<p>Let’s start with this one because it’s a hot button issue. Conservatives and some liberals too have made the claim that state unemployment aid, coupled with $600 a week from the CARES Act, which was rolled out in March 2020, have reduced men’s need to work. (There are actually a variety of social programs at play,spelled out nicely hereby think tank The Century Foundation, which estimates that overall these programs have pumped $800 billion in the economy.) We’ll be getting a good read on whether all this relief did suppress employment now that CARES aid ended for some 7.5 million Americans earlier this month. But as Yahoo Finance’s Denitsa Tsekova reportedhereandhere, states that ended federal aid programs early didn’t see big increases in employment. That may mean these payments really weren’t enough to live off, or not enough to live off by themselves, which speaks to men looking to a combination of sources, like under the table income or family support and possibly some savings (see below).</p>\n<p><b>-Early retirement, pensions, disability and lawsuits</b></p>\n<p>Admittedly, this is a bit of a hodgepodge. And as is the case with many of these categories, hard data is tough to come by, but it is the case that millions of men under 64 are at least partly living off of pensions and 401(k)s. This would include everything from C-suite executives to union members. And don’t forget municipal workers, who make up almost 14% of the U.S. workforce. According to the U.S. Census Bureau, there are some 6,000 public sector retirement systems in the U.S.Collectively these plans have $4.5 trillion in assets,with 14.7 million working members and 11.2 million retirees. The plans distribute $323 billion in benefits annually, and again, some to men who are younger than 64. In fact in almost two-thirds of these plans,if you started working at 25, you max out at 57, a real inducement to stop working — at least at that job of course.</p>\n<p><img src=\"https://static.tigerbbs.com/53e26b293f8a939a54b78315c3375a18\" tg-width=\"705\" tg-height=\"467\" referrerpolicy=\"no-referrer\">Volunteers load cars with turkeys and other food assistance for laid off Walt Disney World cast members and others at a food distribution event on December 12, 2020 in Orlando, Florida. (Photo by Paul Hennessy/NurPhoto via Getty Images)More</p>\n<p>There’s also disability insurance from the Social Security Administration that is beingpaid to some 9 million Americanswhomay receive payments many years before retirement age. That's why I am including disability here, but not plain vanilla Social Security, which you can’t receive until age 62. The maximum disability benefit amount you can receive each month is currently $3,148. (However, the average beneficiary receives about $1,277 per month, according to the law group Social Security Disability Advocates.) Overall, it looks like theSSA pays out some $130 billion in disability annually.That’s not nothing. Then there’s money paid out in medical malpractice each year, smaller true, but stillestimated to be in excess of $3 billion.And don't forgetpayments from legal settlements and class action lawsuits.</p>\n<p>You argue all day about the right or wrong when it comes to these payouts, but the fact is many of them didn’t exist, or not at this magnitude, decades ago.</p>\n<p><b>-Savings, trading stocks, and bitcoin</b></p>\n<p>Consider now men are living off savings, or from money made in the market or maybe even selling NFTs. How many is it exactly? Who knows, but quite a few for sure. First off, Americans on average do have some money in the bank. Savings as a percentage of disposable income,according to the Federal Reserve of Kansas City,hit a record high of 33% in the spring of 2020 and is still at 14%, or nearly twice as high as it was prior to the pandemic.</p>\n<p>And according to arecent survey by Northwestern Mutual,average personal savings are up over 10% compared to last year, from $65,900 last year to $73,100. Average retirement savings increased 13%, from $87,500 last year to $98,800 today. So there’s that.</p>\n<p>Next let’s look at investing — first stocks. It is not irrelevant to this narrative that the S&amp;P 500 has climbed from 2,480 on March 12, 2020 — the day after the World Health Organization declared COVID a pandemic— to 4,441 today, or almost 80%. That’s a huge gain. Much of the action of course has been retail investors and the meme stock boom, as millions of American males stuck at home with nothing to do all day for the past 18 months passed the time trading stocks. Credit Suisse estimates that since the beginning of 2020, “retail trading as a share of overall market activityhas nearly doubledfrom between 15% and 18% to over 30%,” as CNBC reported. How many men were doing this and supporting themselves? Unclear, but upstart trading platform Robinhood (HOOD) — the broker dealer of choice for many of these new investors — reported that it had22.5 million funded user accountslast month, up from 7.2 million in March of 2020. Let’s just say 15 million new accounts is quite a number.</p>\n<p>Now crypto. You can laugh all you want, but the simple fact is that theprice of bitcoinis up from $4,861 on March 12, 2000 to $47,763 today, or basically up 10X, (and remember it even hit $64,888.99 this spring). Back to Robinhood, which according to The New York Times, also reported last month that “revenue from cryptocurrency trading fees totaled $233 million, a nearly 50-fold jump from $5 million a year earlier.” (And those are just fees off the trades, mind you.) Bottom line: Folks have made money here. (Of course these guys should be paying taxes on all those stock and crypto gains.)</p>\n<p><img src=\"https://static.tigerbbs.com/809084435ffdcbc0695311d158bb7a98\" tg-width=\"705\" tg-height=\"470\" referrerpolicy=\"no-referrer\">Robinhood Markets, Inc. CEO and co-founder Vlad Tenev and co-founder Baiju Bhatt pose with Robinhood signage on Wall Street after the company's IPO in New York City, U.S., July 29, 2021. REUTERS/Andrew Kelly<b>-Working for cash, aka the under-the-table economy</b></p>\n<p>This one is very tough to measure, too.A study by the Federal Reserve of St. Louisestimates that the average size of the “informal economy” in developed countries is 13% of GDP. Honestly, that could be off by many percentage points, but just to give you a ballpark, GDP in the U.S. this year is about $22 trillion. So 13% of that is $2.86 trillion. As it turns out, $2 trillion-plus, is a number that has been thrown around quite a bit (hereandherefor instance) when it comes to estimating the size of the cash economy in the U.S. Even if half that money is paid out to women, that still leaves, say, $1 trillion dollars being made by men in this country off the books. That’s a big chunk of change. Are more people than ever working for cash these days? Again, another question that’s impossible to answer. I would bet it’s not fewer. For example, my electrician Luis just told me he can’t get anyone to work for him anymore — they all want to get paid in cash.</p>\n<p><b>-Living off family members</b></p>\n<p>Just to take one facet,the Pew Research Center reportedlast year that the pandemic “has pushed millions of Americans, especially young adults, to move in with family members. The share of 18- to 29-year-olds living with their parents has become a majority since U.S. coronavirus cases began spreading [in early 2020], surpassing the previous peak during the Great Depression era. In July, 52% of young adults resided with one or both of their parents, up from 47% in February.” How many of these individuals are males living rent free (and sharing food too), which maybe means they don’t have to work? Who knows, but some. Ditto for males who have moved in with in-laws or siblings. And again, many men are choosing to stay home and take care of kids while their spouses work.</p>\n<p><b>-Illegal work</b></p>\n<p>Front and center here is selling illegal drugs. Sadly, business looks to be booming, that is if overdoses are any sort of measure.According to the Washington Post, overdose deaths hit 93,000 last year, up a stunning 30% from 2019. Most of the overdoses were attributed to opioids; heroin, synthetic opioids like OxyContin and in particular Fentanyl. (This despite drug dealers facingsupply chain issuesduring COVID.) How many Americans are in this business and who are they? A number is almost impossible to come by here, but as for who they are,a government report on drug trafficking arrestsfrom five years ago notes that ”the majority of drug trafficking offenders were male (84.9%), the average age of these offenders at sentencing was 36 years, 70% were United States citizens (although this rate varied substantially depending on the type of drug involved), and that almost half (49.4%) of drug traffickers had little or no prior criminal history.” How big a business is selling drugs in America? Could beas much as $100 billion.I think it’s fair to say that a market that size requires many thousands of employees.</p>\n<p>What about other types of crime and criminals, everything from robbers and thieves to prostitutes and pimps? To that point there aresome 2 million people incarcerated in the U.S.right now. (We have the highest absolute number and the highest per capita on the planet, and holdsome 25% of the world's total prisoners, according to the ACLU.) Being in prison is another way of living in America without working, I guess. But not counting those locked up, how many bad guys are out there on the street? Conservatively, it has to be thousands and thousands, and speaking to this story, they're all doing their thing and not participating in the labor force.</p>\n<p><img src=\"https://static.tigerbbs.com/3f8f4b3e6a5aa97a10f5c7bb22dec1d7\" tg-width=\"705\" tg-height=\"470\" referrerpolicy=\"no-referrer\">ORLEANS, MASSACHUSETTS - JULY 10: A man holds onto a clamming rake while clamming at low tide July 10, 2021 in Town Cove, Orleans, Massachusetts. He filled a bushel basket of cherry stone clams. (Photo by Robert Nickelsberg/Getty Images)More<b>-Living off the land</b></p>\n<p>This would include gardening, fishing, hunting, clamming, berrying, and just general foraging. The numbers here seem to be climbing. Here for instancefrom The Guardian:</p>\n<p>“Fishing and huntinglicense sales increased 10%in California during the pandemic, reversing years of decline. Clamming has grown in popularity for several reasons: people are looking for safe activities to do outdoors, but also some are clamming for subsistence and trying to get money from selling the shellfish (which is illegal without a commercial license).”</p>\n<p>Ditto for Washington state, according to The Spokesman-Review:</p>\n<p>“From the start of the 2020 licensing year in May through Dec. 31, WDFW [Washington Department of Fish and Wildlife] sold nearly 45,000 more fishing licenses and 12,000 more hunting licenses than 2019. The number of new license holders — defined as someone who hadn’t purchased one for the previous five years — went up 16% for fishing licenses and almost 40% for hunters.”</p>\n<p>As for growing vegetables in home gardens, yes, it is up, way up too. Even before the pandemic, there were estimates thata third of American families grew vegetables.Now this,NPRreported last year:</p>\n<p>“‘We're being flooded with vegetable orders,’ says George Ball, executive chairman of the Burpee Seed Company, based in Warminster, Penn.</p>\n<p>Ball says he has noticed spikes in seed sales during bad times: the stock market crash of 1987, the dot com bubble burst of 2000, and he remembers the two oil crises of the 1970s from his childhood. But he says he has not seen a spike this large and widespread.</p>\n<p>So there you have it. It’s a whole range of ways and means, behaviors and experiences. I’m sure I missed some, too. Again, some non-working men are in dire straits and need our help. Others are living non-working lives without burdening society or others, such as a fireman on early retirement (though some argue municipal employee pensions are too high), or an investor who made a ton of money in the market and called it quits, or maybe a wilderness guy living off the land in Alaska.</p>\n<p>And some non-working men are not playing fair. Like getting paid under the table, fudging insurance claims or social programs. Some freeload off relatives. And some engage in overtly illegal behavior like boosting branded goods from chain stores to sell online or dealing heroin.</p>\n<p>I would imagine that more than a few of these men create a portfolio of sources, though I’m not sure they really think of it that way. Take for example a hypothetical guy in a rural area who lives with his grandmother rent free, (he does help her with the garden some). This guy also does some cash carpentry work, hunts for game, gets some food off his ex-wife’s WIC and helps his brother sell some weed. Can you get by this way? Some men probably are. Is this the new American way? For some men it probably is.</p>\n<p>That example perhaps, and to be sure of all of the above, I think go a long way toward explaining that chart from the beginning of the story, the one that shows the labor participation rate falling off a cliff over the past seven decades. And speaking of charts, another striking one came to mind when I was writing this, which I put here below. It shows U.S. GDP over the same time period as the labor participation rate.</p>\n<p><img src=\"https://static.tigerbbs.com/0f197be5c6c11483ec906a1757293e4d\" tg-width=\"705\" tg-height=\"259\" referrerpolicy=\"no-referrer\">Chart of the U.S. Gross Domestic Product over time, courtesy of the St. Louis Federal Reserve</p>\n<p>Of course, the line on this GDP chart is inversely correlated with the line on the labor participation graph. And I think there is a relationship between the two. Which is to say, the wealthier our nation has become over the decades, the less men are working. Fact is there is just a ton of money sloshing around in our country. And men seem to be able to get their hands on it, whether obtained legally, borrowed, leached off of or stolen.</p>\n<p>It seems like working legally to provide for yourself in America is really just one option these days.</p>\n<p><b><i>This article was featured in a Saturday edition of the Morning Brief on September 18, 2021. Get the Morning Brief sent directly to your inbox every Monday to Friday by 6:30 a.m. ET.Subscribe</i></b></p>\n<p><i>Andy Serwer is editor-in-chief of Yahoo Finance. Follow him on Twitter:@serwer</i></p>","source":"yahoofinance_sg","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 ways men live without working in America</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 ways men live without working in America\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-19 11:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/7-ways-men-live-without-working-in-america-092147068.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Almost one-third of all working-age men in America aren’t doing diddly-squat. They don’t have a job, and they aren’t looking for one either. One-third of all working-age men. That’s almost 30 million ...</p>\n\n<a href=\"https://finance.yahoo.com/news/7-ways-men-live-without-working-in-america-092147068.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/020219c8820f9fc9f11979454ce1b1c6","relate_stocks":{".DJI":"道琼斯"},"source_url":"https://finance.yahoo.com/news/7-ways-men-live-without-working-in-america-092147068.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198486138","content_text":"Almost one-third of all working-age men in America aren’t doing diddly-squat. They don’t have a job, and they aren’t looking for one either. One-third of all working-age men. That’s almost 30 million people!\nHow do they live? What are they doing for money? To me, this is one of the great mysteries of our time.\nI’m certainly not the first person to make note of this shocking statistic. You’ve heard people bemoaning this \"labor participation rate,\" which is simply the number of working-age men (usually counted as ages 16 to 64) not working or not looking for work, as a percentage of the overall labor force.\nIt’s true that the pandemic, which of course produced a number of factors that made working more difficult never mind dangerous, pushed the labor participation rate to a record low. But the fact that millions of American males have not been working precedes COVID-19 by decades. In fact, the participation rate for men peaked at 87.4% in October 1949 and has been dropping steadily ever since. It now stands at 67.7%.\nAs a business journalist for a good portion of those 70-plus years, I’ve looked at thousands of charts and graphs in my life, and I have to say this one is as jaw dropping as it is vexing:\nChart of the U.S. labor force participation rate for men over time, courtesy of the St. Louis Federal Reserve\nEconomists, sociologists, politicians, and cable news pundits each have their pet factors to explain the groundswell of non-work. But after digging down here, I’ve concluded there are many different forces at play. That’s what I want to explore today, which is: how men can live in America without working.\nI’m not talking about why men have lost their jobs — factories closing, layoffs, automation, outsourcing jobs overseas, even perhaps women entering the workforce, (in fact, the participation rate by women over the same time period is way up). What I want to get at is how they’re living without holding a \"real\" job, and by that I mean doing work where one reports income to the IRS, pays taxes and Social Security, etc.\nIt’s important to note that every man in this group has his own story. They range from mentally ill homeless men who desperately need our help, to the I’m-doing-just-fine-thank-you-very-much, retired early, and former Silicon Valley coder. And there are infinite scenarios in between those two extremes, including, for instance, the many men who have chosen to bestay-at-home dadswhile their spouses work.\nIt’s also the case that some men in this group may be unemployed and not seeking work because they’ve given up looking just for now — perhaps waiting for COVID to abate — and will start the search again soon. Here too, society needs to help.\nStill, none of this explains decade after decade of falling male employment.\nTo that end, here to my mind are seven ways men are living without working in America:\n-Unemployment insurance\nLet’s start with this one because it’s a hot button issue. Conservatives and some liberals too have made the claim that state unemployment aid, coupled with $600 a week from the CARES Act, which was rolled out in March 2020, have reduced men’s need to work. (There are actually a variety of social programs at play,spelled out nicely hereby think tank The Century Foundation, which estimates that overall these programs have pumped $800 billion in the economy.) We’ll be getting a good read on whether all this relief did suppress employment now that CARES aid ended for some 7.5 million Americans earlier this month. But as Yahoo Finance’s Denitsa Tsekova reportedhereandhere, states that ended federal aid programs early didn’t see big increases in employment. That may mean these payments really weren’t enough to live off, or not enough to live off by themselves, which speaks to men looking to a combination of sources, like under the table income or family support and possibly some savings (see below).\n-Early retirement, pensions, disability and lawsuits\nAdmittedly, this is a bit of a hodgepodge. And as is the case with many of these categories, hard data is tough to come by, but it is the case that millions of men under 64 are at least partly living off of pensions and 401(k)s. This would include everything from C-suite executives to union members. And don’t forget municipal workers, who make up almost 14% of the U.S. workforce. According to the U.S. Census Bureau, there are some 6,000 public sector retirement systems in the U.S.Collectively these plans have $4.5 trillion in assets,with 14.7 million working members and 11.2 million retirees. The plans distribute $323 billion in benefits annually, and again, some to men who are younger than 64. In fact in almost two-thirds of these plans,if you started working at 25, you max out at 57, a real inducement to stop working — at least at that job of course.\nVolunteers load cars with turkeys and other food assistance for laid off Walt Disney World cast members and others at a food distribution event on December 12, 2020 in Orlando, Florida. (Photo by Paul Hennessy/NurPhoto via Getty Images)More\nThere’s also disability insurance from the Social Security Administration that is beingpaid to some 9 million Americanswhomay receive payments many years before retirement age. That's why I am including disability here, but not plain vanilla Social Security, which you can’t receive until age 62. The maximum disability benefit amount you can receive each month is currently $3,148. (However, the average beneficiary receives about $1,277 per month, according to the law group Social Security Disability Advocates.) Overall, it looks like theSSA pays out some $130 billion in disability annually.That’s not nothing. Then there’s money paid out in medical malpractice each year, smaller true, but stillestimated to be in excess of $3 billion.And don't forgetpayments from legal settlements and class action lawsuits.\nYou argue all day about the right or wrong when it comes to these payouts, but the fact is many of them didn’t exist, or not at this magnitude, decades ago.\n-Savings, trading stocks, and bitcoin\nConsider now men are living off savings, or from money made in the market or maybe even selling NFTs. How many is it exactly? Who knows, but quite a few for sure. First off, Americans on average do have some money in the bank. Savings as a percentage of disposable income,according to the Federal Reserve of Kansas City,hit a record high of 33% in the spring of 2020 and is still at 14%, or nearly twice as high as it was prior to the pandemic.\nAnd according to arecent survey by Northwestern Mutual,average personal savings are up over 10% compared to last year, from $65,900 last year to $73,100. Average retirement savings increased 13%, from $87,500 last year to $98,800 today. So there’s that.\nNext let’s look at investing — first stocks. It is not irrelevant to this narrative that the S&P 500 has climbed from 2,480 on March 12, 2020 — the day after the World Health Organization declared COVID a pandemic— to 4,441 today, or almost 80%. That’s a huge gain. Much of the action of course has been retail investors and the meme stock boom, as millions of American males stuck at home with nothing to do all day for the past 18 months passed the time trading stocks. Credit Suisse estimates that since the beginning of 2020, “retail trading as a share of overall market activityhas nearly doubledfrom between 15% and 18% to over 30%,” as CNBC reported. How many men were doing this and supporting themselves? Unclear, but upstart trading platform Robinhood (HOOD) — the broker dealer of choice for many of these new investors — reported that it had22.5 million funded user accountslast month, up from 7.2 million in March of 2020. Let’s just say 15 million new accounts is quite a number.\nNow crypto. You can laugh all you want, but the simple fact is that theprice of bitcoinis up from $4,861 on March 12, 2000 to $47,763 today, or basically up 10X, (and remember it even hit $64,888.99 this spring). Back to Robinhood, which according to The New York Times, also reported last month that “revenue from cryptocurrency trading fees totaled $233 million, a nearly 50-fold jump from $5 million a year earlier.” (And those are just fees off the trades, mind you.) Bottom line: Folks have made money here. (Of course these guys should be paying taxes on all those stock and crypto gains.)\nRobinhood Markets, Inc. CEO and co-founder Vlad Tenev and co-founder Baiju Bhatt pose with Robinhood signage on Wall Street after the company's IPO in New York City, U.S., July 29, 2021. REUTERS/Andrew Kelly-Working for cash, aka the under-the-table economy\nThis one is very tough to measure, too.A study by the Federal Reserve of St. Louisestimates that the average size of the “informal economy” in developed countries is 13% of GDP. Honestly, that could be off by many percentage points, but just to give you a ballpark, GDP in the U.S. this year is about $22 trillion. So 13% of that is $2.86 trillion. As it turns out, $2 trillion-plus, is a number that has been thrown around quite a bit (hereandherefor instance) when it comes to estimating the size of the cash economy in the U.S. Even if half that money is paid out to women, that still leaves, say, $1 trillion dollars being made by men in this country off the books. That’s a big chunk of change. Are more people than ever working for cash these days? Again, another question that’s impossible to answer. I would bet it’s not fewer. For example, my electrician Luis just told me he can’t get anyone to work for him anymore — they all want to get paid in cash.\n-Living off family members\nJust to take one facet,the Pew Research Center reportedlast year that the pandemic “has pushed millions of Americans, especially young adults, to move in with family members. The share of 18- to 29-year-olds living with their parents has become a majority since U.S. coronavirus cases began spreading [in early 2020], surpassing the previous peak during the Great Depression era. In July, 52% of young adults resided with one or both of their parents, up from 47% in February.” How many of these individuals are males living rent free (and sharing food too), which maybe means they don’t have to work? Who knows, but some. Ditto for males who have moved in with in-laws or siblings. And again, many men are choosing to stay home and take care of kids while their spouses work.\n-Illegal work\nFront and center here is selling illegal drugs. Sadly, business looks to be booming, that is if overdoses are any sort of measure.According to the Washington Post, overdose deaths hit 93,000 last year, up a stunning 30% from 2019. Most of the overdoses were attributed to opioids; heroin, synthetic opioids like OxyContin and in particular Fentanyl. (This despite drug dealers facingsupply chain issuesduring COVID.) How many Americans are in this business and who are they? A number is almost impossible to come by here, but as for who they are,a government report on drug trafficking arrestsfrom five years ago notes that ”the majority of drug trafficking offenders were male (84.9%), the average age of these offenders at sentencing was 36 years, 70% were United States citizens (although this rate varied substantially depending on the type of drug involved), and that almost half (49.4%) of drug traffickers had little or no prior criminal history.” How big a business is selling drugs in America? Could beas much as $100 billion.I think it’s fair to say that a market that size requires many thousands of employees.\nWhat about other types of crime and criminals, everything from robbers and thieves to prostitutes and pimps? To that point there aresome 2 million people incarcerated in the U.S.right now. (We have the highest absolute number and the highest per capita on the planet, and holdsome 25% of the world's total prisoners, according to the ACLU.) Being in prison is another way of living in America without working, I guess. But not counting those locked up, how many bad guys are out there on the street? Conservatively, it has to be thousands and thousands, and speaking to this story, they're all doing their thing and not participating in the labor force.\nORLEANS, MASSACHUSETTS - JULY 10: A man holds onto a clamming rake while clamming at low tide July 10, 2021 in Town Cove, Orleans, Massachusetts. He filled a bushel basket of cherry stone clams. (Photo by Robert Nickelsberg/Getty Images)More-Living off the land\nThis would include gardening, fishing, hunting, clamming, berrying, and just general foraging. The numbers here seem to be climbing. Here for instancefrom The Guardian:\n“Fishing and huntinglicense sales increased 10%in California during the pandemic, reversing years of decline. Clamming has grown in popularity for several reasons: people are looking for safe activities to do outdoors, but also some are clamming for subsistence and trying to get money from selling the shellfish (which is illegal without a commercial license).”\nDitto for Washington state, according to The Spokesman-Review:\n“From the start of the 2020 licensing year in May through Dec. 31, WDFW [Washington Department of Fish and Wildlife] sold nearly 45,000 more fishing licenses and 12,000 more hunting licenses than 2019. The number of new license holders — defined as someone who hadn’t purchased one for the previous five years — went up 16% for fishing licenses and almost 40% for hunters.”\nAs for growing vegetables in home gardens, yes, it is up, way up too. Even before the pandemic, there were estimates thata third of American families grew vegetables.Now this,NPRreported last year:\n“‘We're being flooded with vegetable orders,’ says George Ball, executive chairman of the Burpee Seed Company, based in Warminster, Penn.\nBall says he has noticed spikes in seed sales during bad times: the stock market crash of 1987, the dot com bubble burst of 2000, and he remembers the two oil crises of the 1970s from his childhood. But he says he has not seen a spike this large and widespread.\nSo there you have it. It’s a whole range of ways and means, behaviors and experiences. I’m sure I missed some, too. Again, some non-working men are in dire straits and need our help. Others are living non-working lives without burdening society or others, such as a fireman on early retirement (though some argue municipal employee pensions are too high), or an investor who made a ton of money in the market and called it quits, or maybe a wilderness guy living off the land in Alaska.\nAnd some non-working men are not playing fair. Like getting paid under the table, fudging insurance claims or social programs. Some freeload off relatives. And some engage in overtly illegal behavior like boosting branded goods from chain stores to sell online or dealing heroin.\nI would imagine that more than a few of these men create a portfolio of sources, though I’m not sure they really think of it that way. Take for example a hypothetical guy in a rural area who lives with his grandmother rent free, (he does help her with the garden some). This guy also does some cash carpentry work, hunts for game, gets some food off his ex-wife’s WIC and helps his brother sell some weed. Can you get by this way? Some men probably are. Is this the new American way? For some men it probably is.\nThat example perhaps, and to be sure of all of the above, I think go a long way toward explaining that chart from the beginning of the story, the one that shows the labor participation rate falling off a cliff over the past seven decades. And speaking of charts, another striking one came to mind when I was writing this, which I put here below. It shows U.S. GDP over the same time period as the labor participation rate.\nChart of the U.S. Gross Domestic Product over time, courtesy of the St. Louis Federal Reserve\nOf course, the line on this GDP chart is inversely correlated with the line on the labor participation graph. And I think there is a relationship between the two. Which is to say, the wealthier our nation has become over the decades, the less men are working. Fact is there is just a ton of money sloshing around in our country. And men seem to be able to get their hands on it, whether obtained legally, borrowed, leached off of or stolen.\nIt seems like working legally to provide for yourself in America is really just one option these days.\nThis article was featured in a Saturday edition of the Morning Brief on September 18, 2021. Get the Morning Brief sent directly to your inbox every Monday to Friday by 6:30 a.m. ET.Subscribe\nAndy Serwer is editor-in-chief of Yahoo Finance. Follow him on Twitter:@serwer","news_type":1},"isVote":1,"tweetType":1,"viewCount":197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887941299,"gmtCreate":1631965190611,"gmtModify":1632805055127,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"Their Vote,Your Life.","listText":"Their Vote,Your Life.","text":"Their Vote,Your Life.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/887941299","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","kind":"news","pubTimestamp":1631950800,"share":"https://www.laohu8.com/m/news/2168957763?lang=&edition=full","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885313387,"gmtCreate":1631756267149,"gmtModify":1631888643012,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"Up or down, they will always have a story to tell.","listText":"Up or down, they will always have a story to tell.","text":"Up or down, they will always have a story to tell.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/885313387","repostId":"2167592712","repostType":4,"repost":{"id":"2167592712","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631747120,"share":"https://www.laohu8.com/m/news/2167592712?lang=&edition=full","pubTime":"2021-09-16 07:05","market":"us","language":"en","title":"Wall Street gains as crude price surge, strong economic data prompt broad rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2167592712","media":"Reuters","summary":"NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted ","content":"<p>NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted energy shares and a swath of positive U.S. data suggested inflation has crested and the economic recovery remains robust, boosting investor sentiment.</p>\n<p>All three major U.S. stock indexes gathered strength as the session progressed, with economically sensitive cyclicals, smallcaps and transportation stocks leading the charge.</p>\n<p>While value stocks initially held the advantage, the risk-on sentiment gained momentum through the afternoon, broadening to include growth stocks .</p>\n<p>\"Today is the first time in a while when both growth and value stocks are doing pretty well. It's been either or for much of the last few weeks and today it's both,\" said Chuck Carlson, chief executive of Horizon Investment Services in Hammond, Indiana. \"Breadth matters, and that's something investors like to see.\"</p>\n<p>A host of economic data showed hints of waning inflation and an ongoing return to economic normalcy, even as supply constraints, complicated by hurricane Ida, hindered factory output.</p>\n<p>Import prices posted their first monthly decline since October 2020, in the latest sign that the wave of price spikes has crested, further supporting the Federal Reserve's position that current inflationary pressures are transitory.</p>\n<p>Next week, the Federal Open Markets Committee's two-day monetary policy meeting will be closely parsed for signals as to when the central bank will begin to taper its asset purchases.</p>\n<p>The graphic below shows major indicators against the Fed's average annual 2% inflation target.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 236.82 points, or 0.68%, to 34,814.39; the S&amp;P 500&nbsp;gained 37.65 points, or 0.85%, at 4,480.7; and the Nasdaq Composite&nbsp;added 123.77 points, or 0.82%, at 15,161.53.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, all but utilities&nbsp;gained ground. Energy&nbsp;was by far the biggest gainer, benefiting from a jump in crude prices&nbsp;driven by a drawdown in U.S. stocks.</p>\n<p>U.S.-based casino operators Las Vegas Sands Corp , Wynn Resorts Ltd&nbsp;and MGM Resorts International&nbsp;slid between 1.7% and 6.3%.</p>\n<p>Apple Inc&nbsp;snapped a decline over recent sessions following an adverse court ruling on its business practices, and a lukewarm response to its event on Tuesday where it unveiled updates to its iPhone and other gadgets. Its shares gained 0.6%.</p>\n<p>Lending platform GreenSky Inc&nbsp;shot up 53.2% after Goldman Sachs Group Inc&nbsp;said it would buy the company in an all-stock deal valued at $2.24 billion.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.15-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted seven new 52-week highs and three new lows; the Nasdaq Composite recorded 55 new highs and 106 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street gains as crude price surge, strong economic data prompt broad rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street gains as crude price surge, strong economic data prompt broad rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-16 07:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted energy shares and a swath of positive U.S. data suggested inflation has crested and the economic recovery remains robust, boosting investor sentiment.</p>\n<p>All three major U.S. stock indexes gathered strength as the session progressed, with economically sensitive cyclicals, smallcaps and transportation stocks leading the charge.</p>\n<p>While value stocks initially held the advantage, the risk-on sentiment gained momentum through the afternoon, broadening to include growth stocks .</p>\n<p>\"Today is the first time in a while when both growth and value stocks are doing pretty well. It's been either or for much of the last few weeks and today it's both,\" said Chuck Carlson, chief executive of Horizon Investment Services in Hammond, Indiana. \"Breadth matters, and that's something investors like to see.\"</p>\n<p>A host of economic data showed hints of waning inflation and an ongoing return to economic normalcy, even as supply constraints, complicated by hurricane Ida, hindered factory output.</p>\n<p>Import prices posted their first monthly decline since October 2020, in the latest sign that the wave of price spikes has crested, further supporting the Federal Reserve's position that current inflationary pressures are transitory.</p>\n<p>Next week, the Federal Open Markets Committee's two-day monetary policy meeting will be closely parsed for signals as to when the central bank will begin to taper its asset purchases.</p>\n<p>The graphic below shows major indicators against the Fed's average annual 2% inflation target.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 236.82 points, or 0.68%, to 34,814.39; the S&amp;P 500&nbsp;gained 37.65 points, or 0.85%, at 4,480.7; and the Nasdaq Composite&nbsp;added 123.77 points, or 0.82%, at 15,161.53.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, all but utilities&nbsp;gained ground. Energy&nbsp;was by far the biggest gainer, benefiting from a jump in crude prices&nbsp;driven by a drawdown in U.S. stocks.</p>\n<p>U.S.-based casino operators Las Vegas Sands Corp , Wynn Resorts Ltd&nbsp;and MGM Resorts International&nbsp;slid between 1.7% and 6.3%.</p>\n<p>Apple Inc&nbsp;snapped a decline over recent sessions following an adverse court ruling on its business practices, and a lukewarm response to its event on Tuesday where it unveiled updates to its iPhone and other gadgets. Its shares gained 0.6%.</p>\n<p>Lending platform GreenSky Inc&nbsp;shot up 53.2% after Goldman Sachs Group Inc&nbsp;said it would buy the company in an all-stock deal valued at $2.24 billion.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.15-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted seven new 52-week highs and three new lows; the Nasdaq Composite recorded 55 new highs and 106 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","DDM":"道指两倍做多ETF","SQQQ":"纳指三倍做空ETF","LVS":"金沙集团",".SPX":"S&P 500 Index","DOG":"道指反向ETF","IVV":"标普500指数ETF","QQQ":"纳指100ETF","DJX":"1/100道琼斯","DXD":"道指两倍做空ETF","AAPL":"苹果","WYNN":"永利度假村","SDS":"两倍做空标普500ETF","SDOW":"道指三倍做空ETF-ProShares",".DJI":"道琼斯","SPXU":"三倍做空标普500ETF","QLD":"纳指两倍做多ETF","SSO":"两倍做多标普500ETF","TQQQ":"纳指三倍做多ETF","PSQ":"纳指反向ETF","SH":"标普500反向ETF","MGM":"美高梅","GS":"高盛","QID":"纳指两倍做空ETF","OEX":"标普100",".IXIC":"NASDAQ Composite","UDOW":"道指三倍做多ETF-ProShares","UPRO":"三倍做多标普500ETF","OEF":"标普100指数ETF-iShares"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167592712","content_text":"NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted energy shares and a swath of positive U.S. data suggested inflation has crested and the economic recovery remains robust, boosting investor sentiment.\nAll three major U.S. stock indexes gathered strength as the session progressed, with economically sensitive cyclicals, smallcaps and transportation stocks leading the charge.\nWhile value stocks initially held the advantage, the risk-on sentiment gained momentum through the afternoon, broadening to include growth stocks .\n\"Today is the first time in a while when both growth and value stocks are doing pretty well. It's been either or for much of the last few weeks and today it's both,\" said Chuck Carlson, chief executive of Horizon Investment Services in Hammond, Indiana. \"Breadth matters, and that's something investors like to see.\"\nA host of economic data showed hints of waning inflation and an ongoing return to economic normalcy, even as supply constraints, complicated by hurricane Ida, hindered factory output.\nImport prices posted their first monthly decline since October 2020, in the latest sign that the wave of price spikes has crested, further supporting the Federal Reserve's position that current inflationary pressures are transitory.\nNext week, the Federal Open Markets Committee's two-day monetary policy meeting will be closely parsed for signals as to when the central bank will begin to taper its asset purchases.\nThe graphic below shows major indicators against the Fed's average annual 2% inflation target.\nThe Dow Jones Industrial Average rose 236.82 points, or 0.68%, to 34,814.39; the S&P 500 gained 37.65 points, or 0.85%, at 4,480.7; and the Nasdaq Composite added 123.77 points, or 0.82%, at 15,161.53.\nAmong the 11 major sectors in the S&P 500, all but utilities gained ground. Energy was by far the biggest gainer, benefiting from a jump in crude prices driven by a drawdown in U.S. stocks.\nU.S.-based casino operators Las Vegas Sands Corp , Wynn Resorts Ltd and MGM Resorts International slid between 1.7% and 6.3%.\nApple Inc snapped a decline over recent sessions following an adverse court ruling on its business practices, and a lukewarm response to its event on Tuesday where it unveiled updates to its iPhone and other gadgets. Its shares gained 0.6%.\nLending platform GreenSky Inc shot up 53.2% after Goldman Sachs Group Inc said it would buy the company in an all-stock deal valued at $2.24 billion.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.15-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.\nThe S&P 500 posted seven new 52-week highs and three new lows; the Nasdaq Composite recorded 55 new highs and 106 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818119143,"gmtCreate":1630383029682,"gmtModify":1704959476089,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581689230768222","authorIdStr":"3581689230768222"},"themes":[],"htmlText":"With 80% Population&nbsp;Vaccinated.&nbsp;I Wonder Why&nbsp;SG STI ETF is going down?Will Continue To Collect.&nbsp;","listText":"With 80% Population&nbsp;Vaccinated.&nbsp;I Wonder Why&nbsp;SG STI ETF is going down?Will Continue To Collect.&nbsp;","text":"With 80% Population Vaccinated. I Wonder Why SG STI ETF is going down?Will Continue To Collect.","images":[{"img":"https://static.tigerbbs.com/2249e7eb6ab53f406d33c40603fc3559","width":"1125","height":"2539"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":8,"repostSize":0,"link":"https://laohu8.com/post/818119143","isVote":1,"tweetType":1,"viewCount":486,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000220","authorId":"9000000000000220","name":"揭人不揭短","avatar":"https://static.tigerbbs.com/8a6d90cbff3ceab2e34f58c7b8e0271f","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000220","authorIdStr":"9000000000000220"},"content":"一直买进呀，这个应该在你的成本价下面吧？看着做T很厉害。","text":"一直买进呀，这个应该在你的成本价下面吧？看着做T很厉害。","html":"一直买进呀，这个应该在你的成本价下面吧？看着做T很厉害。"}],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":818119143,"gmtCreate":1630383029682,"gmtModify":1704959476089,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"With 80% Population&nbsp;Vaccinated.&nbsp;I Wonder Why&nbsp;SG STI ETF is going down?Will Continue To Collect.&nbsp;","listText":"With 80% Population&nbsp;Vaccinated.&nbsp;I Wonder Why&nbsp;SG STI ETF is going down?Will Continue To Collect.&nbsp;","text":"With 80% Population Vaccinated. I Wonder Why SG STI ETF is going down?Will Continue To Collect.","images":[{"img":"https://static.tigerbbs.com/2249e7eb6ab53f406d33c40603fc3559","width":"1125","height":"2539"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":8,"repostSize":0,"link":"https://laohu8.com/post/818119143","isVote":1,"tweetType":1,"viewCount":486,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000220","authorId":"9000000000000220","name":"揭人不揭短","avatar":"https://static.tigerbbs.com/8a6d90cbff3ceab2e34f58c7b8e0271f","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"9000000000000220","idStr":"9000000000000220"},"content":"一直买进呀，这个应该在你的成本价下面吧？看着做T很厉害。","text":"一直买进呀，这个应该在你的成本价下面吧？看着做T很厉害。","html":"一直买进呀，这个应该在你的成本价下面吧？看着做T很厉害。"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":872507055,"gmtCreate":1637544086291,"gmtModify":1637544086527,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"👍🏻<a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a>Don’t expect much price movement on or after Ex Div date.&nbsp;If you sell below $3.60, are you making a gain from dividend or are you cutting losses?","listText":"👍🏻<a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a>Don’t expect much price movement on or after Ex Div date.&nbsp;If you sell below $3.60, are you making a gain from dividend or are you cutting losses?","text":"👍🏻$SINGAPORE PRESS HLDGS LTD(T39.SI)$Don’t expect much price movement on or after Ex Div date. If you sell below $3.60, are you making a gain from dividend or are you cutting losses?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/872507055","repostId":"1174499408","repostType":4,"isVote":1,"tweetType":1,"viewCount":1109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859675674,"gmtCreate":1634695896769,"gmtModify":1634695897230,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"title":"Patient For Profit","htmlText":"<a href=\"https://laohu8.com/S/ES3.SI\">$STI ETF(ES3.SI)$</a>Most people don’t make profit because they are too quick to sell.&nbsp;You need to and your homework and believe in your work.&nbsp;Buy when the price drop and wait paitiently for the price to reach your selling range before you take profit.&nbsp;Talk is simple.&nbsp;True Wealth G.P.S Daddy walk his talk.&nbsp;","listText":"<a href=\"https://laohu8.com/S/ES3.SI\">$STI ETF(ES3.SI)$</a>Most people don’t make profit because they are too quick to sell.&nbsp;You need to and your homework and believe in your work.&nbsp;Buy when the price drop and wait paitiently for the price to reach your selling range before you take profit.&nbsp;Talk is simple.&nbsp;True Wealth G.P.S Daddy walk his talk.&nbsp;","text":"$STI ETF(ES3.SI)$Most people don’t make profit because they are too quick to sell. You need to and your homework and believe in your work. Buy when the price drop and wait paitiently for the price to reach your selling range before you take profit. Talk is simple. True Wealth G.P.S Daddy walk his talk.","images":[{"img":"https://static.tigerbbs.com/cf4f49424aa17e01e18e867bceb180b4","width":"1242","height":"2208"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/859675674","isVote":1,"tweetType":1,"viewCount":1036,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":885313387,"gmtCreate":1631756267149,"gmtModify":1631888643012,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"Up or down, they will always have a story to tell.","listText":"Up or down, they will always have a story to tell.","text":"Up or down, they will always have a story to tell.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/885313387","repostId":"2167592712","repostType":4,"repost":{"id":"2167592712","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631747120,"share":"https://www.laohu8.com/m/news/2167592712?lang=&edition=full","pubTime":"2021-09-16 07:05","market":"us","language":"en","title":"Wall Street gains as crude price surge, strong economic data prompt broad rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2167592712","media":"Reuters","summary":"NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted ","content":"<p>NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted energy shares and a swath of positive U.S. data suggested inflation has crested and the economic recovery remains robust, boosting investor sentiment.</p>\n<p>All three major U.S. stock indexes gathered strength as the session progressed, with economically sensitive cyclicals, smallcaps and transportation stocks leading the charge.</p>\n<p>While value stocks initially held the advantage, the risk-on sentiment gained momentum through the afternoon, broadening to include growth stocks .</p>\n<p>\"Today is the first time in a while when both growth and value stocks are doing pretty well. It's been either or for much of the last few weeks and today it's both,\" said Chuck Carlson, chief executive of Horizon Investment Services in Hammond, Indiana. \"Breadth matters, and that's something investors like to see.\"</p>\n<p>A host of economic data showed hints of waning inflation and an ongoing return to economic normalcy, even as supply constraints, complicated by hurricane Ida, hindered factory output.</p>\n<p>Import prices posted their first monthly decline since October 2020, in the latest sign that the wave of price spikes has crested, further supporting the Federal Reserve's position that current inflationary pressures are transitory.</p>\n<p>Next week, the Federal Open Markets Committee's two-day monetary policy meeting will be closely parsed for signals as to when the central bank will begin to taper its asset purchases.</p>\n<p>The graphic below shows major indicators against the Fed's average annual 2% inflation target.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 236.82 points, or 0.68%, to 34,814.39; the S&amp;P 500&nbsp;gained 37.65 points, or 0.85%, at 4,480.7; and the Nasdaq Composite&nbsp;added 123.77 points, or 0.82%, at 15,161.53.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, all but utilities&nbsp;gained ground. Energy&nbsp;was by far the biggest gainer, benefiting from a jump in crude prices&nbsp;driven by a drawdown in U.S. stocks.</p>\n<p>U.S.-based casino operators Las Vegas Sands Corp , Wynn Resorts Ltd&nbsp;and MGM Resorts International&nbsp;slid between 1.7% and 6.3%.</p>\n<p>Apple Inc&nbsp;snapped a decline over recent sessions following an adverse court ruling on its business practices, and a lukewarm response to its event on Tuesday where it unveiled updates to its iPhone and other gadgets. Its shares gained 0.6%.</p>\n<p>Lending platform GreenSky Inc&nbsp;shot up 53.2% after Goldman Sachs Group Inc&nbsp;said it would buy the company in an all-stock deal valued at $2.24 billion.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.15-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted seven new 52-week highs and three new lows; the Nasdaq Composite recorded 55 new highs and 106 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street gains as crude price surge, strong economic data prompt broad rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street gains as crude price surge, strong economic data prompt broad rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-16 07:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted energy shares and a swath of positive U.S. data suggested inflation has crested and the economic recovery remains robust, boosting investor sentiment.</p>\n<p>All three major U.S. stock indexes gathered strength as the session progressed, with economically sensitive cyclicals, smallcaps and transportation stocks leading the charge.</p>\n<p>While value stocks initially held the advantage, the risk-on sentiment gained momentum through the afternoon, broadening to include growth stocks .</p>\n<p>\"Today is the first time in a while when both growth and value stocks are doing pretty well. It's been either or for much of the last few weeks and today it's both,\" said Chuck Carlson, chief executive of Horizon Investment Services in Hammond, Indiana. \"Breadth matters, and that's something investors like to see.\"</p>\n<p>A host of economic data showed hints of waning inflation and an ongoing return to economic normalcy, even as supply constraints, complicated by hurricane Ida, hindered factory output.</p>\n<p>Import prices posted their first monthly decline since October 2020, in the latest sign that the wave of price spikes has crested, further supporting the Federal Reserve's position that current inflationary pressures are transitory.</p>\n<p>Next week, the Federal Open Markets Committee's two-day monetary policy meeting will be closely parsed for signals as to when the central bank will begin to taper its asset purchases.</p>\n<p>The graphic below shows major indicators against the Fed's average annual 2% inflation target.</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 236.82 points, or 0.68%, to 34,814.39; the S&amp;P 500&nbsp;gained 37.65 points, or 0.85%, at 4,480.7; and the Nasdaq Composite&nbsp;added 123.77 points, or 0.82%, at 15,161.53.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, all but utilities&nbsp;gained ground. Energy&nbsp;was by far the biggest gainer, benefiting from a jump in crude prices&nbsp;driven by a drawdown in U.S. stocks.</p>\n<p>U.S.-based casino operators Las Vegas Sands Corp , Wynn Resorts Ltd&nbsp;and MGM Resorts International&nbsp;slid between 1.7% and 6.3%.</p>\n<p>Apple Inc&nbsp;snapped a decline over recent sessions following an adverse court ruling on its business practices, and a lukewarm response to its event on Tuesday where it unveiled updates to its iPhone and other gadgets. Its shares gained 0.6%.</p>\n<p>Lending platform GreenSky Inc&nbsp;shot up 53.2% after Goldman Sachs Group Inc&nbsp;said it would buy the company in an all-stock deal valued at $2.24 billion.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.15-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted seven new 52-week highs and three new lows; the Nasdaq Composite recorded 55 new highs and 106 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","DDM":"道指两倍做多ETF","SQQQ":"纳指三倍做空ETF","LVS":"金沙集团",".SPX":"S&P 500 Index","DOG":"道指反向ETF","IVV":"标普500指数ETF","QQQ":"纳指100ETF","DJX":"1/100道琼斯","DXD":"道指两倍做空ETF","AAPL":"苹果","WYNN":"永利度假村","SDS":"两倍做空标普500ETF","SDOW":"道指三倍做空ETF-ProShares",".DJI":"道琼斯","SPXU":"三倍做空标普500ETF","QLD":"纳指两倍做多ETF","SSO":"两倍做多标普500ETF","TQQQ":"纳指三倍做多ETF","PSQ":"纳指反向ETF","SH":"标普500反向ETF","MGM":"美高梅","GS":"高盛","QID":"纳指两倍做空ETF","OEX":"标普100",".IXIC":"NASDAQ Composite","UDOW":"道指三倍做多ETF-ProShares","UPRO":"三倍做多标普500ETF","OEF":"标普100指数ETF-iShares"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167592712","content_text":"NEW YORK, Sept 15 (Reuters) - U.S. stocks closed higher on Wednesday as rising crude prices boosted energy shares and a swath of positive U.S. data suggested inflation has crested and the economic recovery remains robust, boosting investor sentiment.\nAll three major U.S. stock indexes gathered strength as the session progressed, with economically sensitive cyclicals, smallcaps and transportation stocks leading the charge.\nWhile value stocks initially held the advantage, the risk-on sentiment gained momentum through the afternoon, broadening to include growth stocks .\n\"Today is the first time in a while when both growth and value stocks are doing pretty well. It's been either or for much of the last few weeks and today it's both,\" said Chuck Carlson, chief executive of Horizon Investment Services in Hammond, Indiana. \"Breadth matters, and that's something investors like to see.\"\nA host of economic data showed hints of waning inflation and an ongoing return to economic normalcy, even as supply constraints, complicated by hurricane Ida, hindered factory output.\nImport prices posted their first monthly decline since October 2020, in the latest sign that the wave of price spikes has crested, further supporting the Federal Reserve's position that current inflationary pressures are transitory.\nNext week, the Federal Open Markets Committee's two-day monetary policy meeting will be closely parsed for signals as to when the central bank will begin to taper its asset purchases.\nThe graphic below shows major indicators against the Fed's average annual 2% inflation target.\nThe Dow Jones Industrial Average rose 236.82 points, or 0.68%, to 34,814.39; the S&P 500 gained 37.65 points, or 0.85%, at 4,480.7; and the Nasdaq Composite added 123.77 points, or 0.82%, at 15,161.53.\nAmong the 11 major sectors in the S&P 500, all but utilities gained ground. Energy was by far the biggest gainer, benefiting from a jump in crude prices driven by a drawdown in U.S. stocks.\nU.S.-based casino operators Las Vegas Sands Corp , Wynn Resorts Ltd and MGM Resorts International slid between 1.7% and 6.3%.\nApple Inc snapped a decline over recent sessions following an adverse court ruling on its business practices, and a lukewarm response to its event on Tuesday where it unveiled updates to its iPhone and other gadgets. Its shares gained 0.6%.\nLending platform GreenSky Inc shot up 53.2% after Goldman Sachs Group Inc said it would buy the company in an all-stock deal valued at $2.24 billion.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.15-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.\nThe S&P 500 posted seven new 52-week highs and three new lows; the Nasdaq Composite recorded 55 new highs and 106 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887941299,"gmtCreate":1631965190611,"gmtModify":1632805055127,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"Their Vote,Your Life.","listText":"Their Vote,Your Life.","text":"Their Vote,Your Life.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/887941299","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","kind":"news","pubTimestamp":1631950800,"share":"https://www.laohu8.com/m/news/2168957763?lang=&edition=full","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":101,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":873521275,"gmtCreate":1636964532977,"gmtModify":1636964533511,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"Did her dumping value add to the funds?","listText":"Did her dumping value add to the funds?","text":"Did her dumping value add to the funds?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873521275","repostId":"2183046479","repostType":4,"repost":{"id":"2183046479","kind":"highlight","pubTimestamp":1636962804,"share":"https://www.laohu8.com/m/news/2183046479?lang=&edition=full","pubTime":"2021-11-15 15:53","market":"us","language":"en","title":"Cathie Wood Goes Dumpster Diving: 3 Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2183046479","media":"Motley Fool","summary":"A trio of stocks you might consider adding to your portfolio.","content":"<p>Cathie Wood runs one(AONE.U) of the most popular tech stock funds, the <b>ARK Innovation Fund </b>(NYSEMKT:ARKK), with more than $19 billion under management. This fund is not only popular, but it is also soundly beating the <b>S&amp;P 500</b> with a five-year return of 39% annually (as of Sept. 30).&nbsp;Cathie Wood runs this fund and seven other tech-focused funds that are popular with growth investors. One of the things that makes her a popular investor to follow is that all the buys and sells from these funds are published daily.</p>\n<p>Since she has a history of picking high-tech stocks at good prices, we asked three Motley Fool contributors to highlight one company that her funds have purchased recently that investors should consider adding to their portfolio.</p>\n<p>They came up with <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> </b>(NASDAQ:FB), <b>Palantir</b> (NYSE:PLTR), and <b>Twilio</b> (NYSE:TWLO).</p>\n<h2>Meta Platforms: The company formerly known as Facebook</h2>\n<p><b>Danny Vena (Meta Platforms): </b>The <b><a href=\"https://laohu8.com/S/ARKF\">ARK Fintech Innovation ETF</a></b> has made some bold moves lately, no doubt spurred on by Cathie Wood's vision of the future. One of the biggest purchases over the past week is the addition of a big chunk of Meta Platforms, the company formerly known as Facebook.</p>\n<p>Over the past week, the fund has stockpiled more than 100,000 shares of Meta, worth more than $33 million (as of this writing). Perhaps more importantly, ARK Fintech Innovation already had a substantial stake in Meta, now equal to a roughly 3% position, and valued at nearly $103 million -- making it the fund's 11th largest position.</p>\n<p>Meta has been working to debut its long-awaited digital currency dubbed Diem, formerly known as Libra. The company is a founding member of the Diem Association, which underpins the upcoming cryptocurrency.&nbsp;Diem is a blockchain-based payment system that was designed from the ground up with payments in mind, focusing on \"consumer safety, financial stability, and combating financial crime.\"</p>\n<p>Additionally, just last month, Meta launched a pilot of Novi -- its cryptocurrency wallet -- to a small number of users in the U.S. and Guatemala.</p>\n<p>Given Wood's early adoption and bullish track record regarding <b>Bitcoin</b>, it's little wonder the rock star investor might place a similar bet on a Meta-backed cryptocurrency and digital wallet. But those fintech aspirations notwithstanding, there are plenty of other reasons to be bullish on Meta.</p>\n<p>Let's not forget that Facebook is one of the most recognized companies on the planet. For the third quarter, Facebook reported 1.93 billion daily active users (DAUs), up 6% year over year, and 2.91 billion monthly active users (MAUs). When you expand that to include the company's other platforms (Instagram, WhatsApp, and Messenger) that rises to 2.81 billion DAUs and 3.58 billion MAUs.</p>\n<p>That many users creates a powerful network effect for the social media baron, helping Meta generate significant advertising revenue to support its moonshots. In the third quarter, revenue of $29 billion grew 35% year over year -- even as the company dealt with privacy reforms rolled out by <b>Apple</b>, which made it more difficult to measure the success of advertising campaigns across devices using iOS. Meta also generated more than $9.1 billion in net income and $9.5 billion in free cash flow.</p>\n<p>Even as the company faces regulatory challenges, Meta is preparing for the metaverse, a digital realm online where users play, work, and shop. Meta describes this as \"the next evolution of social connection ... [where] you'll be able to socialize, learn, collaborate and play in ways that go beyond what's possible today.\"</p>\n<p>Meta sees the metaverse as its next big growth driver, as well as a way to retain young, tech savvy users. The company has a head start in the areas of augmented reality (AR) and virtual-reality, which will likely be key components in its broader strategy.</p>\n<p>It also doesn't hurt that the stock is on sale at a 15% discount to recent highs.</p>\n<h2>Palantir: Wood continues adding shares to this insight seeker</h2>\n<p><b>Will Healy</b> <b>(Palantir): </b>Palantir stands out from other data companies in that it specializes in delivering insights. The company works with national security and law enforcement organizations through its Gotham software, functionality that has everyone talking about Palantir stock.</p>\n<p>Moreover, the company has also developed a product for the commercial space, called Foundry, which currently drives the company's fastest growth.</p>\n<p>Seeing the potential of these products, Wood has accumulated Palantir shares in the ARK Innovation Fund since February, buying multiple lots with only one sale in September. This has taken the total in that fund to more than 24 million shares, a 2.8% weighting. Wood has added Palantir shares less aggressively to the <b>ARK Industrial Innovation ETF</b>. Nonetheless, more than 1.1 million Palantir shares make up about 1% of this fund.</p>\n<p>Palantir reported strong numbers in its third-quarter 2021 earnings report. Third-quarter revenue of $392 million surged 36% from year-ago levels. This led to an adjusted net income of $82 million. Palantir also raised fourth-quarter guidance, and predicted the $418 million in revenue will rise 30% year over year if that number holds.</p>\n<p>Nonetheless, the stock dropped 9% in Tuesday trading as the company forecast an adjusted operating margin of 22% for Q4. Analysts had expected 24%. Moreover, a government document indicated that U.S. Immigration and Customs Enforcement (ICE) might replace Palantir's system with a competing product, though a recent U.S. Army contract could mitigate that loss.</p>\n<p>Additionally, while Wood bought just under 1 million shares between the two funds on that day, the stock fell an additional 7% on Wednesday. With that move, Palantir stock wipes out all of its 2021 gains and has fallen 4% in 2021 as of the time of this writing. Also, despite that drop, Palantir trades at a price-to-sales (P/S) ratio of 27, well above the average S&amp;P 500 stock, which sells at just over three times sales.</p>\n<p>With its data insight capabilities, Palantir's massive revenue growth should continue. However, given the high sales multiple and the stock falling on a mostly favorable earnings report, investors may not want to follow Wood's lead in the near term.</p>\n<h2>Twilio: Expanding its mission</h2>\n<p><b>Brian Withers (Twilio): </b>Twilio announced earnings on Oct. 28, and the stock took a 17% haircut the next day. Since then, Cathie Wood's ARK funds snapped up over 415,000 shares of the stock representing about $122 million. These buys moved this customer communication platform specialist to the 12th largest holding across its funds. Let take a look at why she might be buying massive quantities of this tech company, which appears to be on sale.</p>\n<p>First, let's look at the quarterly results and why investors may have been spooked. The top line grew at a massive 65% year over year, but subtracting the contributions for the Zipwhip and Segment.io acquisitions, the year-over-year growth drops to 38%. This is a deceleration from the last four quarters of organic year-over-year growth that were between 47% and 54%. This slowdown was one reason for the stock sell-off, the other was likely the growing losses. Expenses increased faster than revenue this quarter and the company more than doubled its operating loss year over year.</p>\n<table>\n <thead>\n  <tr>\n   <th><p>Metrics</p></th>\n   <th><p>Q3 2020</p></th>\n   <th><p>Q2 2021</p></th>\n   <th><p>Q3 2021</p></th>\n   <th><p>Change (QOQ)</p></th>\n   <th><p>Change (YOY)</p></th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td><p>Revenue</p></td>\n   <td><p>$448 million</p></td>\n   <td><p>$669 million</p></td>\n   <td><p>$740 million</p></td>\n   <td><p>11%</p></td>\n   <td><p>65%</p></td>\n  </tr>\n  <tr>\n   <td><p>Organic revenue</p></td>\n   <td><p>$438 million</p></td>\n   <td><p>$590 million</p></td>\n   <td><p>$606 million</p></td>\n   <td><p>3%</p></td>\n   <td><p>38%</p></td>\n  </tr>\n  <tr>\n   <td><p>Operating income (loss)</p></td>\n   <td><p>($112 million)</p></td>\n   <td><p>($227 million)</p></td>\n   <td><p>($232 million)</p></td>\n   <td><p>n/a</p></td>\n   <td><p>n/a</p></td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Company earnings release. QOQ = quarter over quarter. YOY = year over year.</p>\n<p>But one quarter doesn't make a trend and this company's got a lot up its sleeve. It just announced its Twilio Engage platform which takes advantage of the integration of Segment.io's customer data platform and Twilio's core messaging services. This new product will enable businesses to personalize messages based on customer behaviors and will make the messages customers receive even more relevant to their needs.</p>\n<p>Lastly, the company has updated its mission. For the last 13 years, the mission has been \"Fuel the Future of Communications.\" Today the mission is broader, focusing on its core user, the software developer. It is to \"Unlock the Imagination of Builders.\" This may not make any impact this quarter or even in the coming year. But over time, this allows the company to expand beyond just its communication products.</p>\n<p>With the stock more than 30% off its high, it could be a good time to jump in and pick up some shares yourself. You probably won't be buying in the amount that the ARK funds have, but even if you just add a few shares today, in five years, it's likely you'll be very happy you did.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Dumpster Diving: 3 Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Dumpster Diving: 3 Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 15:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/14/cathie-wood-goes-dumpster-diving-3-stocks-she-just/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood runs one(AONE.U) of the most popular tech stock funds, the ARK Innovation Fund (NYSEMKT:ARKK), with more than $19 billion under management. This fund is not only popular, but it is also ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/14/cathie-wood-goes-dumpster-diving-3-stocks-she-just/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWLO":"Twilio Inc","PLTR":"Palantir Technologies Inc."},"source_url":"https://www.fool.com/investing/2021/11/14/cathie-wood-goes-dumpster-diving-3-stocks-she-just/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183046479","content_text":"Cathie Wood runs one(AONE.U) of the most popular tech stock funds, the ARK Innovation Fund (NYSEMKT:ARKK), with more than $19 billion under management. This fund is not only popular, but it is also soundly beating the S&P 500 with a five-year return of 39% annually (as of Sept. 30). Cathie Wood runs this fund and seven other tech-focused funds that are popular with growth investors. One of the things that makes her a popular investor to follow is that all the buys and sells from these funds are published daily.\nSince she has a history of picking high-tech stocks at good prices, we asked three Motley Fool contributors to highlight one company that her funds have purchased recently that investors should consider adding to their portfolio.\nThey came up with Meta Platforms (NASDAQ:FB), Palantir (NYSE:PLTR), and Twilio (NYSE:TWLO).\nMeta Platforms: The company formerly known as Facebook\nDanny Vena (Meta Platforms): The ARK Fintech Innovation ETF has made some bold moves lately, no doubt spurred on by Cathie Wood's vision of the future. One of the biggest purchases over the past week is the addition of a big chunk of Meta Platforms, the company formerly known as Facebook.\nOver the past week, the fund has stockpiled more than 100,000 shares of Meta, worth more than $33 million (as of this writing). Perhaps more importantly, ARK Fintech Innovation already had a substantial stake in Meta, now equal to a roughly 3% position, and valued at nearly $103 million -- making it the fund's 11th largest position.\nMeta has been working to debut its long-awaited digital currency dubbed Diem, formerly known as Libra. The company is a founding member of the Diem Association, which underpins the upcoming cryptocurrency. Diem is a blockchain-based payment system that was designed from the ground up with payments in mind, focusing on \"consumer safety, financial stability, and combating financial crime.\"\nAdditionally, just last month, Meta launched a pilot of Novi -- its cryptocurrency wallet -- to a small number of users in the U.S. and Guatemala.\nGiven Wood's early adoption and bullish track record regarding Bitcoin, it's little wonder the rock star investor might place a similar bet on a Meta-backed cryptocurrency and digital wallet. But those fintech aspirations notwithstanding, there are plenty of other reasons to be bullish on Meta.\nLet's not forget that Facebook is one of the most recognized companies on the planet. For the third quarter, Facebook reported 1.93 billion daily active users (DAUs), up 6% year over year, and 2.91 billion monthly active users (MAUs). When you expand that to include the company's other platforms (Instagram, WhatsApp, and Messenger) that rises to 2.81 billion DAUs and 3.58 billion MAUs.\nThat many users creates a powerful network effect for the social media baron, helping Meta generate significant advertising revenue to support its moonshots. In the third quarter, revenue of $29 billion grew 35% year over year -- even as the company dealt with privacy reforms rolled out by Apple, which made it more difficult to measure the success of advertising campaigns across devices using iOS. Meta also generated more than $9.1 billion in net income and $9.5 billion in free cash flow.\nEven as the company faces regulatory challenges, Meta is preparing for the metaverse, a digital realm online where users play, work, and shop. Meta describes this as \"the next evolution of social connection ... [where] you'll be able to socialize, learn, collaborate and play in ways that go beyond what's possible today.\"\nMeta sees the metaverse as its next big growth driver, as well as a way to retain young, tech savvy users. The company has a head start in the areas of augmented reality (AR) and virtual-reality, which will likely be key components in its broader strategy.\nIt also doesn't hurt that the stock is on sale at a 15% discount to recent highs.\nPalantir: Wood continues adding shares to this insight seeker\nWill Healy (Palantir): Palantir stands out from other data companies in that it specializes in delivering insights. The company works with national security and law enforcement organizations through its Gotham software, functionality that has everyone talking about Palantir stock.\nMoreover, the company has also developed a product for the commercial space, called Foundry, which currently drives the company's fastest growth.\nSeeing the potential of these products, Wood has accumulated Palantir shares in the ARK Innovation Fund since February, buying multiple lots with only one sale in September. This has taken the total in that fund to more than 24 million shares, a 2.8% weighting. Wood has added Palantir shares less aggressively to the ARK Industrial Innovation ETF. Nonetheless, more than 1.1 million Palantir shares make up about 1% of this fund.\nPalantir reported strong numbers in its third-quarter 2021 earnings report. Third-quarter revenue of $392 million surged 36% from year-ago levels. This led to an adjusted net income of $82 million. Palantir also raised fourth-quarter guidance, and predicted the $418 million in revenue will rise 30% year over year if that number holds.\nNonetheless, the stock dropped 9% in Tuesday trading as the company forecast an adjusted operating margin of 22% for Q4. Analysts had expected 24%. Moreover, a government document indicated that U.S. Immigration and Customs Enforcement (ICE) might replace Palantir's system with a competing product, though a recent U.S. Army contract could mitigate that loss.\nAdditionally, while Wood bought just under 1 million shares between the two funds on that day, the stock fell an additional 7% on Wednesday. With that move, Palantir stock wipes out all of its 2021 gains and has fallen 4% in 2021 as of the time of this writing. Also, despite that drop, Palantir trades at a price-to-sales (P/S) ratio of 27, well above the average S&P 500 stock, which sells at just over three times sales.\nWith its data insight capabilities, Palantir's massive revenue growth should continue. However, given the high sales multiple and the stock falling on a mostly favorable earnings report, investors may not want to follow Wood's lead in the near term.\nTwilio: Expanding its mission\nBrian Withers (Twilio): Twilio announced earnings on Oct. 28, and the stock took a 17% haircut the next day. Since then, Cathie Wood's ARK funds snapped up over 415,000 shares of the stock representing about $122 million. These buys moved this customer communication platform specialist to the 12th largest holding across its funds. Let take a look at why she might be buying massive quantities of this tech company, which appears to be on sale.\nFirst, let's look at the quarterly results and why investors may have been spooked. The top line grew at a massive 65% year over year, but subtracting the contributions for the Zipwhip and Segment.io acquisitions, the year-over-year growth drops to 38%. This is a deceleration from the last four quarters of organic year-over-year growth that were between 47% and 54%. This slowdown was one reason for the stock sell-off, the other was likely the growing losses. Expenses increased faster than revenue this quarter and the company more than doubled its operating loss year over year.\n\n\n\nMetrics\nQ3 2020\nQ2 2021\nQ3 2021\nChange (QOQ)\nChange (YOY)\n\n\n\n\nRevenue\n$448 million\n$669 million\n$740 million\n11%\n65%\n\n\nOrganic revenue\n$438 million\n$590 million\n$606 million\n3%\n38%\n\n\nOperating income (loss)\n($112 million)\n($227 million)\n($232 million)\nn/a\nn/a\n\n\n\nData source: Company earnings release. QOQ = quarter over quarter. YOY = year over year.\nBut one quarter doesn't make a trend and this company's got a lot up its sleeve. It just announced its Twilio Engage platform which takes advantage of the integration of Segment.io's customer data platform and Twilio's core messaging services. This new product will enable businesses to personalize messages based on customer behaviors and will make the messages customers receive even more relevant to their needs.\nLastly, the company has updated its mission. For the last 13 years, the mission has been \"Fuel the Future of Communications.\" Today the mission is broader, focusing on its core user, the software developer. It is to \"Unlock the Imagination of Builders.\" This may not make any impact this quarter or even in the coming year. But over time, this allows the company to expand beyond just its communication products.\nWith the stock more than 30% off its high, it could be a good time to jump in and pick up some shares yourself. You probably won't be buying in the amount that the ARK funds have, but even if you just add a few shares today, in five years, it's likely you'll be very happy you did.","news_type":1},"isVote":1,"tweetType":1,"viewCount":808,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":869689576,"gmtCreate":1632279965995,"gmtModify":1632801518539,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"All you want is $$$. Here that it and leave me alone!","listText":"All you want is $$$. Here that it and leave me alone!","text":"All you want is $$$. Here that it and leave me alone!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/869689576","repostId":"2169658327","repostType":4,"repost":{"id":"2169658327","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1632278040,"share":"https://www.laohu8.com/m/news/2169658327?lang=&edition=full","pubTime":"2021-09-22 10:34","market":"us","language":"en","title":"Facebook overpaid FTC fine as 'quid pro quo' to protect Zuckerberg from liability, shareholders claim","url":"https://stock-news.laohu8.com/highlight/detail?id=2169658327","media":"Dow Jones","summary":"Lawsuits claim directors protected CEO from being held personally liable for Cambridge Analytica bre","content":"<p>Lawsuits claim directors protected CEO from being held personally liable for Cambridge Analytica breach</p>\n<p>Facebook Inc. overpaid billions of dollars to the Federal Trade Commission as part of an agreement to keep CEO Mark Zuckerberg from being personally sued, shareholders claim in a pair of lawsuits.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> separate groups of Facebook (FB) shareholders filed suit Tuesday, Politico first reported, alleging that Facebook's board approved an over-payment on its settlement with the FTC over the Cambridge Analytica scandal to protect Zuckerberg.</p>\n<p>One of the lawsuits claimed that in early 2019, a draft complaint from the FTC named both Facebook and Zuckerberg as defendants.</p>\n<p>The suit cited minutes from a subsequent Facebook board meeting, and claimed \"Zuckerberg, [COO Sheryl] Sandberg, and other Facebook directors agreed to authorize a multi-billion settlement with the FTC as an express quid pro quo to protect Zuckerberg from being named in the FTC's complaint, made subject to personal liability, or even required to sit for a deposition.\"</p>\n<p>Also read:Facebook to review its practice of separate rules for high-profile users</p>\n<p>In July 2019, Facebook agreed to pay the FTC a record fine of $5 billion to settle the investigation into the Cambridge Analytics data breach.</p>\n<p>The suit was filed on behalf of the Employees' Retirement System of Rhode Island and the City of Warwick (R.I.) Retirement System.</p>\n<p>The second lawsuit also claimed Facebook has failed in its obligation to protect the private data of its users, and alleged that the Cambridge Analytics' data scraping was a \"destined consequence\" of Facebook's business plan.</p>\n<p>Plaintiffs in that suit include the California State Teachers' Retirement System, New York's construction and laborers' Local No. 79 general fund, the City of Birmingham (Ala.) retirement system and Firemen's Retirement System of St. Louis.</p>\n<p>Facebook did not immediately respond for a request for comment Tuesday night.</p>\n<p>Facebook shares have fallen 5% over the past week, following a revelatory series of investigations by the Wall Street Journal, which the company called a collection of \"mischaracterizations.\" But the stock is still up 31% year to date, compared to the S&amp;P 500's 16% gain.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook overpaid FTC fine as 'quid pro quo' to protect Zuckerberg from liability, shareholders claim</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook overpaid FTC fine as 'quid pro quo' to protect Zuckerberg from liability, shareholders claim\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-22 10:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Lawsuits claim directors protected CEO from being held personally liable for Cambridge Analytica breach</p>\n<p>Facebook Inc. overpaid billions of dollars to the Federal Trade Commission as part of an agreement to keep CEO Mark Zuckerberg from being personally sued, shareholders claim in a pair of lawsuits.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> separate groups of Facebook (FB) shareholders filed suit Tuesday, Politico first reported, alleging that Facebook's board approved an over-payment on its settlement with the FTC over the Cambridge Analytica scandal to protect Zuckerberg.</p>\n<p>One of the lawsuits claimed that in early 2019, a draft complaint from the FTC named both Facebook and Zuckerberg as defendants.</p>\n<p>The suit cited minutes from a subsequent Facebook board meeting, and claimed \"Zuckerberg, [COO Sheryl] Sandberg, and other Facebook directors agreed to authorize a multi-billion settlement with the FTC as an express quid pro quo to protect Zuckerberg from being named in the FTC's complaint, made subject to personal liability, or even required to sit for a deposition.\"</p>\n<p>Also read:Facebook to review its practice of separate rules for high-profile users</p>\n<p>In July 2019, Facebook agreed to pay the FTC a record fine of $5 billion to settle the investigation into the Cambridge Analytics data breach.</p>\n<p>The suit was filed on behalf of the Employees' Retirement System of Rhode Island and the City of Warwick (R.I.) Retirement System.</p>\n<p>The second lawsuit also claimed Facebook has failed in its obligation to protect the private data of its users, and alleged that the Cambridge Analytics' data scraping was a \"destined consequence\" of Facebook's business plan.</p>\n<p>Plaintiffs in that suit include the California State Teachers' Retirement System, New York's construction and laborers' Local No. 79 general fund, the City of Birmingham (Ala.) retirement system and Firemen's Retirement System of St. Louis.</p>\n<p>Facebook did not immediately respond for a request for comment Tuesday night.</p>\n<p>Facebook shares have fallen 5% over the past week, following a revelatory series of investigations by the Wall Street Journal, which the company called a collection of \"mischaracterizations.\" But the stock is still up 31% year to date, compared to the S&amp;P 500's 16% gain.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169658327","content_text":"Lawsuits claim directors protected CEO from being held personally liable for Cambridge Analytica breach\nFacebook Inc. overpaid billions of dollars to the Federal Trade Commission as part of an agreement to keep CEO Mark Zuckerberg from being personally sued, shareholders claim in a pair of lawsuits.\nTwo separate groups of Facebook (FB) shareholders filed suit Tuesday, Politico first reported, alleging that Facebook's board approved an over-payment on its settlement with the FTC over the Cambridge Analytica scandal to protect Zuckerberg.\nOne of the lawsuits claimed that in early 2019, a draft complaint from the FTC named both Facebook and Zuckerberg as defendants.\nThe suit cited minutes from a subsequent Facebook board meeting, and claimed \"Zuckerberg, [COO Sheryl] Sandberg, and other Facebook directors agreed to authorize a multi-billion settlement with the FTC as an express quid pro quo to protect Zuckerberg from being named in the FTC's complaint, made subject to personal liability, or even required to sit for a deposition.\"\nAlso read:Facebook to review its practice of separate rules for high-profile users\nIn July 2019, Facebook agreed to pay the FTC a record fine of $5 billion to settle the investigation into the Cambridge Analytics data breach.\nThe suit was filed on behalf of the Employees' Retirement System of Rhode Island and the City of Warwick (R.I.) Retirement System.\nThe second lawsuit also claimed Facebook has failed in its obligation to protect the private data of its users, and alleged that the Cambridge Analytics' data scraping was a \"destined consequence\" of Facebook's business plan.\nPlaintiffs in that suit include the California State Teachers' Retirement System, New York's construction and laborers' Local No. 79 general fund, the City of Birmingham (Ala.) retirement system and Firemen's Retirement System of St. Louis.\nFacebook did not immediately respond for a request for comment Tuesday night.\nFacebook shares have fallen 5% over the past week, following a revelatory series of investigations by the Wall Street Journal, which the company called a collection of \"mischaracterizations.\" But the stock is still up 31% year to date, compared to the S&P 500's 16% gain.","news_type":1},"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":607036402,"gmtCreate":1639455056578,"gmtModify":1639458879625,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"If Bitcoin is Gold.What is Dogcoin?It seem now a month or two, a new coin is born.&nbsp;If now and then a new coin can be born, how valuable can your coin be in the future?","listText":"If Bitcoin is Gold.What is Dogcoin?It seem now a month or two, a new coin is born.&nbsp;If now and then a new coin can be born, how valuable can your coin be in the future?","text":"If Bitcoin is Gold.What is Dogcoin?It seem now a month or two, a new coin is born. If now and then a new coin can be born, how valuable can your coin be in the future?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/607036402","repostId":"1134867438","repostType":4,"repost":{"id":"1134867438","kind":"news","pubTimestamp":1639447985,"share":"https://www.laohu8.com/m/news/1134867438?lang=&edition=full","pubTime":"2021-12-14 10:13","market":"us","language":"en","title":"Bitcoin is About 90% Mined Out","url":"https://stock-news.laohu8.com/highlight/detail?id=1134867438","media":"the street","summary":"Bitcoin crossed an important milestone Monday with 90% of the finite cryptocurrency being mined, acc","content":"<p>Bitcoin crossed an important milestone Monday with 90% of the finite cryptocurrency being mined, according to Blockchain.com.</p>\n<p></p>\n<p>About 18.89 million bitcoins, out of a maximum of 21 million, have been mined and are now available to be bought and sold.</p>\n<p></p>\n<p>It took 12 years for the world's largest cryptocurrency by market cap to reach that goal after the first coins were mined on Jan. 9, 2009.</p>\n<p></p>\n<p>However, it will take exponentially longer for the remaining supply to mined due to bitcoin's halving schedule. The halving schedule is an inflationary control device where the reward for mining bitcoin is cut in half.</p>\n<p></p>\n<p>This also cuts in half bitcoin's inflation rate and the rate at which new bitcoins enter circulation.</p>\n<p></p>\n<p>Bitcoin halving occurs on average about once every four years after 210,000 blocks are mined. At that rate, bitcoin isn't expected to be fully mined until February 2140, according to CoinDesk.</p>\n<p></p>\n<p>Bitcoin's blockchain relies on the proof of work model, where miners solve complex mathematical equations that authenticate transactions on the blockchain. Those miners are rewarded with bitcoin.</p>\n<p></p>\n<p>However, with the halving schedules in place, their reward is cut in half at certain intervals, discouraging more mining as the cost of equipment and energy to mine can be prohibitive.</p>\n<p></p>\n<p>Bitcoin prices have taken a dive in recent weeks, falling more than 6% over the past five days and 26% over the past month.</p>\n<p></p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bitcoin is About 90% Mined Out</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBitcoin is About 90% Mined Out\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 10:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/bitcoin-reaches-mining-threshold><strong>the street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bitcoin crossed an important milestone Monday with 90% of the finite cryptocurrency being mined, according to Blockchain.com.\n\nAbout 18.89 million bitcoins, out of a maximum of 21 million, have been ...</p>\n\n<a href=\"https://www.thestreet.com/investing/bitcoin-reaches-mining-threshold\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://www.thestreet.com/investing/bitcoin-reaches-mining-threshold","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134867438","content_text":"Bitcoin crossed an important milestone Monday with 90% of the finite cryptocurrency being mined, according to Blockchain.com.\n\nAbout 18.89 million bitcoins, out of a maximum of 21 million, have been mined and are now available to be bought and sold.\n\nIt took 12 years for the world's largest cryptocurrency by market cap to reach that goal after the first coins were mined on Jan. 9, 2009.\n\nHowever, it will take exponentially longer for the remaining supply to mined due to bitcoin's halving schedule. The halving schedule is an inflationary control device where the reward for mining bitcoin is cut in half.\n\nThis also cuts in half bitcoin's inflation rate and the rate at which new bitcoins enter circulation.\n\nBitcoin halving occurs on average about once every four years after 210,000 blocks are mined. At that rate, bitcoin isn't expected to be fully mined until February 2140, according to CoinDesk.\n\nBitcoin's blockchain relies on the proof of work model, where miners solve complex mathematical equations that authenticate transactions on the blockchain. Those miners are rewarded with bitcoin.\n\nHowever, with the halving schedules in place, their reward is cut in half at certain intervals, discouraging more mining as the cost of equipment and energy to mine can be prohibitive.\n\nBitcoin prices have taken a dive in recent weeks, falling more than 6% over the past five days and 26% over the past month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":778,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870810989,"gmtCreate":1636598902047,"gmtModify":1636598902187,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"It a risk.&nbsp;But will be interesting if Keppel don’t follow through their offer.&nbsp;Since 2.351 is final offer.&nbsp;Anyone who really want SHP only need to offer 2.352 or higher to beat Keppel.&nbsp;=\\\\=There is still some profit to be made.&nbsp;Not forgetting up coming div of,&nbsp;$0.03?","listText":"It a risk.&nbsp;But will be interesting if Keppel don’t follow through their offer.&nbsp;Since 2.351 is final offer.&nbsp;Anyone who really want SHP only need to offer 2.352 or higher to beat Keppel.&nbsp;=\\\\=There is still some profit to be made.&nbsp;Not forgetting up coming div of,&nbsp;$0.03?","text":"It a risk. But will be interesting if Keppel don’t follow through their offer. Since 2.351 is final offer. Anyone who really want SHP only need to offer 2.352 or higher to beat Keppel. =\\\\=There is still some profit to be made. Not forgetting up coming div of, $0.03?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/870810989","repostId":"1183617975","repostType":4,"repost":{"id":"1183617975","kind":"news","pubTimestamp":1636597438,"share":"https://www.laohu8.com/m/news/1183617975?lang=&edition=full","pubTime":"2021-11-11 10:23","market":"us","language":"en","title":"Hot stocks: SPH, SPH Reit, Keppel, Keppel Reit see active trading after Keppel's counter offer for SPH","url":"https://stock-news.laohu8.com/highlight/detail?id=1183617975","media":"The bussiness Times","summary":"SHARES of Singapore Press Holdings (SPH) and Keppel Corp, as well as units of SPH Reit and Keppel Re","content":"<p>SHARES of Singapore Press Holdings (SPH) and Keppel Corp, as well as units of SPH Reit and Keppel Reit, were actively traded in the morning on Thursday (Nov 11), after Keppel said it would raise its privatisation offer for SPH.</p>\n<p>SPH and Keppel Reit were among the top traded counters by volume in the morning.</p>\n<p>As at 9 am, SPH reached a high of S$2.30, up S$0.14 or 6.5 per cent, with 3 million shares changing hands. Keppel Reit reached a low of S$1.09, down S$0.06 or 5.2 per cent, with 4.1 million units traded.</p>\n<p>Meanwhile, Keppel Corp fell to S$5.26 as at 9.18 am, down S$0.05 or 0.9 per cent, with 560,700 shares changing hands. SPH Reit was down S$0.03 or 2.9 per cent at S$0.99 as at 9 am, with 244,500 units traded.</p>\n<p>As at 9.43 am, SPH shares eased slightly to S$2.28, up S$0.12 or 5.6 per cent, with 13.6 million shares changing hands. SPH Reit was trading at S$0.995, down S$0.025 or 2.5 per cent, with 3.7 million units traded.</p>\n<p>Keppel shares were down S$0.03 or 0.6 per cent at S$5.28, with 996,200 shares changing hands, while Keppel Reit slipped S$0.04 or 3.5 per cent to S$1.11, with 9.7 million units traded.</p>\n<p>Late Tuesday night, Keppel announced it would raise its privatisation offer for SPH to S$2.351 per share by beefing up its cash component. The final offer comprises cash of S$0.868 per share, 0.596 Keppel Reit unit (valued at S$0.685 as at Nov 9) and 0.782 SPH Reit unit (valued S$0.798 as at Nov 9) per SPH share.</p>\n<p>Keppel said its revised offer price reflects a change of conditions, stemming from an improved financial performance and the overall economic environment since July.</p>\n<p>The higher cash consideration, however, is expected to increase Keppel's pro forma net gearing by 0.03 time after the transaction, although the group's pro forma net gearing should remain below 1 time.</p>\n<p>SPH, SPH Reit, Keppel and Keppel Reit called for trading halts on Wednesday (Nov 10) morning, for the dissemination of announcements. All 4 counters have since resumed trading.</p>","source":"lsy1636420184263","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot stocks: SPH, SPH Reit, Keppel, Keppel Reit see active trading after Keppel's counter offer for SPH</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot stocks: SPH, SPH Reit, Keppel, Keppel Reit see active trading after Keppel's counter offer for SPH\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-11 10:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/stocks/hot-stocks-sph-sph-reit-keppel-keppel-reit-see-active-trading-after-keppels-counter-offer-for><strong>The bussiness Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SHARES of Singapore Press Holdings (SPH) and Keppel Corp, as well as units of SPH Reit and Keppel Reit, were actively traded in the morning on Thursday (Nov 11), after Keppel said it would raise its ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/stocks/hot-stocks-sph-sph-reit-keppel-keppel-reit-see-active-trading-after-keppels-counter-offer-for\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BN4.SI":"吉宝有限公司"},"source_url":"https://www.businesstimes.com.sg/stocks/hot-stocks-sph-sph-reit-keppel-keppel-reit-see-active-trading-after-keppels-counter-offer-for","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183617975","content_text":"SHARES of Singapore Press Holdings (SPH) and Keppel Corp, as well as units of SPH Reit and Keppel Reit, were actively traded in the morning on Thursday (Nov 11), after Keppel said it would raise its privatisation offer for SPH.\nSPH and Keppel Reit were among the top traded counters by volume in the morning.\nAs at 9 am, SPH reached a high of S$2.30, up S$0.14 or 6.5 per cent, with 3 million shares changing hands. Keppel Reit reached a low of S$1.09, down S$0.06 or 5.2 per cent, with 4.1 million units traded.\nMeanwhile, Keppel Corp fell to S$5.26 as at 9.18 am, down S$0.05 or 0.9 per cent, with 560,700 shares changing hands. SPH Reit was down S$0.03 or 2.9 per cent at S$0.99 as at 9 am, with 244,500 units traded.\nAs at 9.43 am, SPH shares eased slightly to S$2.28, up S$0.12 or 5.6 per cent, with 13.6 million shares changing hands. SPH Reit was trading at S$0.995, down S$0.025 or 2.5 per cent, with 3.7 million units traded.\nKeppel shares were down S$0.03 or 0.6 per cent at S$5.28, with 996,200 shares changing hands, while Keppel Reit slipped S$0.04 or 3.5 per cent to S$1.11, with 9.7 million units traded.\nLate Tuesday night, Keppel announced it would raise its privatisation offer for SPH to S$2.351 per share by beefing up its cash component. The final offer comprises cash of S$0.868 per share, 0.596 Keppel Reit unit (valued at S$0.685 as at Nov 9) and 0.782 SPH Reit unit (valued S$0.798 as at Nov 9) per SPH share.\nKeppel said its revised offer price reflects a change of conditions, stemming from an improved financial performance and the overall economic environment since July.\nThe higher cash consideration, however, is expected to increase Keppel's pro forma net gearing by 0.03 time after the transaction, although the group's pro forma net gearing should remain below 1 time.\nSPH, SPH Reit, Keppel and Keppel Reit called for trading halts on Wednesday (Nov 10) morning, for the dissemination of announcements. All 4 counters have since resumed trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870895246,"gmtCreate":1636597966619,"gmtModify":1636597981085,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"Buy<a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a><a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a>Current Price Is Lower Than The Offer Price","listText":"Buy<a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a><a href=\"https://laohu8.com/S/T39.SI\">$SINGAPORE PRESS HLDGS LTD(T39.SI)$</a>Current Price Is Lower Than The Offer Price","text":"Buy$SINGAPORE PRESS HLDGS LTD(T39.SI)$$SINGAPORE PRESS HLDGS LTD(T39.SI)$Current Price Is Lower Than The Offer Price","images":[{"img":"https://static.tigerbbs.com/15ca968203cbfcc5b2b2ae4a2c1273ec","width":"1242","height":"2208"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/870895246","isVote":1,"tweetType":1,"viewCount":1143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":887684315,"gmtCreate":1632027245537,"gmtModify":1632803234512,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"Trading is perhaps the 8th way men live without working in the World.","listText":"Trading is perhaps the 8th way men live without working in the World.","text":"Trading is perhaps the 8th way men live without working in the World.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/887684315","repostId":"1198486138","repostType":4,"repost":{"id":"1198486138","kind":"news","pubTimestamp":1632023224,"share":"https://www.laohu8.com/m/news/1198486138?lang=&edition=full","pubTime":"2021-09-19 11:47","market":"us","language":"en","title":"7 ways men live without working in America","url":"https://stock-news.laohu8.com/highlight/detail?id=1198486138","media":"Yahoo Finance","summary":"How do they live? What are they doing for money? ","content":"<p>Almost one-third of all working-age men in America aren’t doing diddly-squat. They don’t have a job, and they aren’t looking for one either. One-third of all working-age men. That’s almost 30 million people!</p>\n<p>How do they live? What are they doing for money? To me, this is one of the great mysteries of our time.</p>\n<p>I’m certainly not the first person to make note of this shocking statistic. You’ve heard people bemoaning this \"labor participation rate,\" which is simply the number of working-age men (usually counted as ages 16 to 64) not working or not looking for work, as a percentage of the overall labor force.</p>\n<p>It’s true that the pandemic, which of course produced a number of factors that made working more difficult never mind dangerous, pushed the labor participation rate to a record low. But the fact that millions of American males have not been working precedes COVID-19 by decades. In fact, the participation rate for men peaked at 87.4% in October 1949 and has been dropping steadily ever since. It now stands at 67.7%.</p>\n<p>As a business journalist for a good portion of those 70-plus years, I’ve looked at thousands of charts and graphs in my life, and I have to say this one is as jaw dropping as it is vexing:</p>\n<p><img src=\"https://static.tigerbbs.com/056158b8fa7157238c3d1521dd05c02e\" tg-width=\"705\" tg-height=\"259\" referrerpolicy=\"no-referrer\">Chart of the U.S. labor force participation rate for men over time, courtesy of the St. Louis Federal Reserve</p>\n<p>Economists, sociologists, politicians, and cable news pundits each have their pet factors to explain the groundswell of non-work. But after digging down here, I’ve concluded there are many different forces at play. That’s what I want to explore today, which is: how men can live in America without working.</p>\n<p>I’m not talking about why men have lost their jobs — factories closing, layoffs, automation, outsourcing jobs overseas, even perhaps women entering the workforce, (in fact, the participation rate by women over the same time period is way up). What I want to get at is how they’re living without holding a \"real\" job, and by that I mean doing work where one reports income to the IRS, pays taxes and Social Security, etc.</p>\n<p>It’s important to note that every man in this group has his own story. They range from mentally ill homeless men who desperately need our help, to the I’m-doing-just-fine-thank-you-very-much, retired early, and former Silicon Valley coder. And there are infinite scenarios in between those two extremes, including, for instance, the many men who have chosen to bestay-at-home dadswhile their spouses work.</p>\n<p>It’s also the case that some men in this group may be unemployed and not seeking work because they’ve given up looking just for now — perhaps waiting for COVID to abate — and will start the search again soon. Here too, society needs to help.</p>\n<p>Still, none of this explains decade after decade of falling male employment.</p>\n<p>To that end, here to my mind are seven ways men are living without working in America:</p>\n<p><b>-Unemployment insurance</b></p>\n<p>Let’s start with this one because it’s a hot button issue. Conservatives and some liberals too have made the claim that state unemployment aid, coupled with $600 a week from the CARES Act, which was rolled out in March 2020, have reduced men’s need to work. (There are actually a variety of social programs at play,spelled out nicely hereby think tank The Century Foundation, which estimates that overall these programs have pumped $800 billion in the economy.) We’ll be getting a good read on whether all this relief did suppress employment now that CARES aid ended for some 7.5 million Americans earlier this month. But as Yahoo Finance’s Denitsa Tsekova reportedhereandhere, states that ended federal aid programs early didn’t see big increases in employment. That may mean these payments really weren’t enough to live off, or not enough to live off by themselves, which speaks to men looking to a combination of sources, like under the table income or family support and possibly some savings (see below).</p>\n<p><b>-Early retirement, pensions, disability and lawsuits</b></p>\n<p>Admittedly, this is a bit of a hodgepodge. And as is the case with many of these categories, hard data is tough to come by, but it is the case that millions of men under 64 are at least partly living off of pensions and 401(k)s. This would include everything from C-suite executives to union members. And don’t forget municipal workers, who make up almost 14% of the U.S. workforce. According to the U.S. Census Bureau, there are some 6,000 public sector retirement systems in the U.S.Collectively these plans have $4.5 trillion in assets,with 14.7 million working members and 11.2 million retirees. The plans distribute $323 billion in benefits annually, and again, some to men who are younger than 64. In fact in almost two-thirds of these plans,if you started working at 25, you max out at 57, a real inducement to stop working — at least at that job of course.</p>\n<p><img src=\"https://static.tigerbbs.com/53e26b293f8a939a54b78315c3375a18\" tg-width=\"705\" tg-height=\"467\" referrerpolicy=\"no-referrer\">Volunteers load cars with turkeys and other food assistance for laid off Walt Disney World cast members and others at a food distribution event on December 12, 2020 in Orlando, Florida. (Photo by Paul Hennessy/NurPhoto via Getty Images)More</p>\n<p>There’s also disability insurance from the Social Security Administration that is beingpaid to some 9 million Americanswhomay receive payments many years before retirement age. That's why I am including disability here, but not plain vanilla Social Security, which you can’t receive until age 62. The maximum disability benefit amount you can receive each month is currently $3,148. (However, the average beneficiary receives about $1,277 per month, according to the law group Social Security Disability Advocates.) Overall, it looks like theSSA pays out some $130 billion in disability annually.That’s not nothing. Then there’s money paid out in medical malpractice each year, smaller true, but stillestimated to be in excess of $3 billion.And don't forgetpayments from legal settlements and class action lawsuits.</p>\n<p>You argue all day about the right or wrong when it comes to these payouts, but the fact is many of them didn’t exist, or not at this magnitude, decades ago.</p>\n<p><b>-Savings, trading stocks, and bitcoin</b></p>\n<p>Consider now men are living off savings, or from money made in the market or maybe even selling NFTs. How many is it exactly? Who knows, but quite a few for sure. First off, Americans on average do have some money in the bank. Savings as a percentage of disposable income,according to the Federal Reserve of Kansas City,hit a record high of 33% in the spring of 2020 and is still at 14%, or nearly twice as high as it was prior to the pandemic.</p>\n<p>And according to arecent survey by Northwestern Mutual,average personal savings are up over 10% compared to last year, from $65,900 last year to $73,100. Average retirement savings increased 13%, from $87,500 last year to $98,800 today. So there’s that.</p>\n<p>Next let’s look at investing — first stocks. It is not irrelevant to this narrative that the S&amp;P 500 has climbed from 2,480 on March 12, 2020 — the day after the World Health Organization declared COVID a pandemic— to 4,441 today, or almost 80%. That’s a huge gain. Much of the action of course has been retail investors and the meme stock boom, as millions of American males stuck at home with nothing to do all day for the past 18 months passed the time trading stocks. Credit Suisse estimates that since the beginning of 2020, “retail trading as a share of overall market activityhas nearly doubledfrom between 15% and 18% to over 30%,” as CNBC reported. How many men were doing this and supporting themselves? Unclear, but upstart trading platform Robinhood (HOOD) — the broker dealer of choice for many of these new investors — reported that it had22.5 million funded user accountslast month, up from 7.2 million in March of 2020. Let’s just say 15 million new accounts is quite a number.</p>\n<p>Now crypto. You can laugh all you want, but the simple fact is that theprice of bitcoinis up from $4,861 on March 12, 2000 to $47,763 today, or basically up 10X, (and remember it even hit $64,888.99 this spring). Back to Robinhood, which according to The New York Times, also reported last month that “revenue from cryptocurrency trading fees totaled $233 million, a nearly 50-fold jump from $5 million a year earlier.” (And those are just fees off the trades, mind you.) Bottom line: Folks have made money here. (Of course these guys should be paying taxes on all those stock and crypto gains.)</p>\n<p><img src=\"https://static.tigerbbs.com/809084435ffdcbc0695311d158bb7a98\" tg-width=\"705\" tg-height=\"470\" referrerpolicy=\"no-referrer\">Robinhood Markets, Inc. CEO and co-founder Vlad Tenev and co-founder Baiju Bhatt pose with Robinhood signage on Wall Street after the company's IPO in New York City, U.S., July 29, 2021. REUTERS/Andrew Kelly<b>-Working for cash, aka the under-the-table economy</b></p>\n<p>This one is very tough to measure, too.A study by the Federal Reserve of St. Louisestimates that the average size of the “informal economy” in developed countries is 13% of GDP. Honestly, that could be off by many percentage points, but just to give you a ballpark, GDP in the U.S. this year is about $22 trillion. So 13% of that is $2.86 trillion. As it turns out, $2 trillion-plus, is a number that has been thrown around quite a bit (hereandherefor instance) when it comes to estimating the size of the cash economy in the U.S. Even if half that money is paid out to women, that still leaves, say, $1 trillion dollars being made by men in this country off the books. That’s a big chunk of change. Are more people than ever working for cash these days? Again, another question that’s impossible to answer. I would bet it’s not fewer. For example, my electrician Luis just told me he can’t get anyone to work for him anymore — they all want to get paid in cash.</p>\n<p><b>-Living off family members</b></p>\n<p>Just to take one facet,the Pew Research Center reportedlast year that the pandemic “has pushed millions of Americans, especially young adults, to move in with family members. The share of 18- to 29-year-olds living with their parents has become a majority since U.S. coronavirus cases began spreading [in early 2020], surpassing the previous peak during the Great Depression era. In July, 52% of young adults resided with one or both of their parents, up from 47% in February.” How many of these individuals are males living rent free (and sharing food too), which maybe means they don’t have to work? Who knows, but some. Ditto for males who have moved in with in-laws or siblings. And again, many men are choosing to stay home and take care of kids while their spouses work.</p>\n<p><b>-Illegal work</b></p>\n<p>Front and center here is selling illegal drugs. Sadly, business looks to be booming, that is if overdoses are any sort of measure.According to the Washington Post, overdose deaths hit 93,000 last year, up a stunning 30% from 2019. Most of the overdoses were attributed to opioids; heroin, synthetic opioids like OxyContin and in particular Fentanyl. (This despite drug dealers facingsupply chain issuesduring COVID.) How many Americans are in this business and who are they? A number is almost impossible to come by here, but as for who they are,a government report on drug trafficking arrestsfrom five years ago notes that ”the majority of drug trafficking offenders were male (84.9%), the average age of these offenders at sentencing was 36 years, 70% were United States citizens (although this rate varied substantially depending on the type of drug involved), and that almost half (49.4%) of drug traffickers had little or no prior criminal history.” How big a business is selling drugs in America? Could beas much as $100 billion.I think it’s fair to say that a market that size requires many thousands of employees.</p>\n<p>What about other types of crime and criminals, everything from robbers and thieves to prostitutes and pimps? To that point there aresome 2 million people incarcerated in the U.S.right now. (We have the highest absolute number and the highest per capita on the planet, and holdsome 25% of the world's total prisoners, according to the ACLU.) Being in prison is another way of living in America without working, I guess. But not counting those locked up, how many bad guys are out there on the street? Conservatively, it has to be thousands and thousands, and speaking to this story, they're all doing their thing and not participating in the labor force.</p>\n<p><img src=\"https://static.tigerbbs.com/3f8f4b3e6a5aa97a10f5c7bb22dec1d7\" tg-width=\"705\" tg-height=\"470\" referrerpolicy=\"no-referrer\">ORLEANS, MASSACHUSETTS - JULY 10: A man holds onto a clamming rake while clamming at low tide July 10, 2021 in Town Cove, Orleans, Massachusetts. He filled a bushel basket of cherry stone clams. (Photo by Robert Nickelsberg/Getty Images)More<b>-Living off the land</b></p>\n<p>This would include gardening, fishing, hunting, clamming, berrying, and just general foraging. The numbers here seem to be climbing. Here for instancefrom The Guardian:</p>\n<p>“Fishing and huntinglicense sales increased 10%in California during the pandemic, reversing years of decline. Clamming has grown in popularity for several reasons: people are looking for safe activities to do outdoors, but also some are clamming for subsistence and trying to get money from selling the shellfish (which is illegal without a commercial license).”</p>\n<p>Ditto for Washington state, according to The Spokesman-Review:</p>\n<p>“From the start of the 2020 licensing year in May through Dec. 31, WDFW [Washington Department of Fish and Wildlife] sold nearly 45,000 more fishing licenses and 12,000 more hunting licenses than 2019. The number of new license holders — defined as someone who hadn’t purchased one for the previous five years — went up 16% for fishing licenses and almost 40% for hunters.”</p>\n<p>As for growing vegetables in home gardens, yes, it is up, way up too. Even before the pandemic, there were estimates thata third of American families grew vegetables.Now this,NPRreported last year:</p>\n<p>“‘We're being flooded with vegetable orders,’ says George Ball, executive chairman of the Burpee Seed Company, based in Warminster, Penn.</p>\n<p>Ball says he has noticed spikes in seed sales during bad times: the stock market crash of 1987, the dot com bubble burst of 2000, and he remembers the two oil crises of the 1970s from his childhood. But he says he has not seen a spike this large and widespread.</p>\n<p>So there you have it. It’s a whole range of ways and means, behaviors and experiences. I’m sure I missed some, too. Again, some non-working men are in dire straits and need our help. Others are living non-working lives without burdening society or others, such as a fireman on early retirement (though some argue municipal employee pensions are too high), or an investor who made a ton of money in the market and called it quits, or maybe a wilderness guy living off the land in Alaska.</p>\n<p>And some non-working men are not playing fair. Like getting paid under the table, fudging insurance claims or social programs. Some freeload off relatives. And some engage in overtly illegal behavior like boosting branded goods from chain stores to sell online or dealing heroin.</p>\n<p>I would imagine that more than a few of these men create a portfolio of sources, though I’m not sure they really think of it that way. Take for example a hypothetical guy in a rural area who lives with his grandmother rent free, (he does help her with the garden some). This guy also does some cash carpentry work, hunts for game, gets some food off his ex-wife’s WIC and helps his brother sell some weed. Can you get by this way? Some men probably are. Is this the new American way? For some men it probably is.</p>\n<p>That example perhaps, and to be sure of all of the above, I think go a long way toward explaining that chart from the beginning of the story, the one that shows the labor participation rate falling off a cliff over the past seven decades. And speaking of charts, another striking one came to mind when I was writing this, which I put here below. It shows U.S. GDP over the same time period as the labor participation rate.</p>\n<p><img src=\"https://static.tigerbbs.com/0f197be5c6c11483ec906a1757293e4d\" tg-width=\"705\" tg-height=\"259\" referrerpolicy=\"no-referrer\">Chart of the U.S. Gross Domestic Product over time, courtesy of the St. Louis Federal Reserve</p>\n<p>Of course, the line on this GDP chart is inversely correlated with the line on the labor participation graph. And I think there is a relationship between the two. Which is to say, the wealthier our nation has become over the decades, the less men are working. Fact is there is just a ton of money sloshing around in our country. And men seem to be able to get their hands on it, whether obtained legally, borrowed, leached off of or stolen.</p>\n<p>It seems like working legally to provide for yourself in America is really just one option these days.</p>\n<p><b><i>This article was featured in a Saturday edition of the Morning Brief on September 18, 2021. Get the Morning Brief sent directly to your inbox every Monday to Friday by 6:30 a.m. ET.Subscribe</i></b></p>\n<p><i>Andy Serwer is editor-in-chief of Yahoo Finance. Follow him on Twitter:@serwer</i></p>","source":"yahoofinance_sg","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 ways men live without working in America</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 ways men live without working in America\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-19 11:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/7-ways-men-live-without-working-in-america-092147068.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Almost one-third of all working-age men in America aren’t doing diddly-squat. They don’t have a job, and they aren’t looking for one either. One-third of all working-age men. That’s almost 30 million ...</p>\n\n<a href=\"https://finance.yahoo.com/news/7-ways-men-live-without-working-in-america-092147068.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/020219c8820f9fc9f11979454ce1b1c6","relate_stocks":{".DJI":"道琼斯"},"source_url":"https://finance.yahoo.com/news/7-ways-men-live-without-working-in-america-092147068.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198486138","content_text":"Almost one-third of all working-age men in America aren’t doing diddly-squat. They don’t have a job, and they aren’t looking for one either. One-third of all working-age men. That’s almost 30 million people!\nHow do they live? What are they doing for money? To me, this is one of the great mysteries of our time.\nI’m certainly not the first person to make note of this shocking statistic. You’ve heard people bemoaning this \"labor participation rate,\" which is simply the number of working-age men (usually counted as ages 16 to 64) not working or not looking for work, as a percentage of the overall labor force.\nIt’s true that the pandemic, which of course produced a number of factors that made working more difficult never mind dangerous, pushed the labor participation rate to a record low. But the fact that millions of American males have not been working precedes COVID-19 by decades. In fact, the participation rate for men peaked at 87.4% in October 1949 and has been dropping steadily ever since. It now stands at 67.7%.\nAs a business journalist for a good portion of those 70-plus years, I’ve looked at thousands of charts and graphs in my life, and I have to say this one is as jaw dropping as it is vexing:\nChart of the U.S. labor force participation rate for men over time, courtesy of the St. Louis Federal Reserve\nEconomists, sociologists, politicians, and cable news pundits each have their pet factors to explain the groundswell of non-work. But after digging down here, I’ve concluded there are many different forces at play. That’s what I want to explore today, which is: how men can live in America without working.\nI’m not talking about why men have lost their jobs — factories closing, layoffs, automation, outsourcing jobs overseas, even perhaps women entering the workforce, (in fact, the participation rate by women over the same time period is way up). What I want to get at is how they’re living without holding a \"real\" job, and by that I mean doing work where one reports income to the IRS, pays taxes and Social Security, etc.\nIt’s important to note that every man in this group has his own story. They range from mentally ill homeless men who desperately need our help, to the I’m-doing-just-fine-thank-you-very-much, retired early, and former Silicon Valley coder. And there are infinite scenarios in between those two extremes, including, for instance, the many men who have chosen to bestay-at-home dadswhile their spouses work.\nIt’s also the case that some men in this group may be unemployed and not seeking work because they’ve given up looking just for now — perhaps waiting for COVID to abate — and will start the search again soon. Here too, society needs to help.\nStill, none of this explains decade after decade of falling male employment.\nTo that end, here to my mind are seven ways men are living without working in America:\n-Unemployment insurance\nLet’s start with this one because it’s a hot button issue. Conservatives and some liberals too have made the claim that state unemployment aid, coupled with $600 a week from the CARES Act, which was rolled out in March 2020, have reduced men’s need to work. (There are actually a variety of social programs at play,spelled out nicely hereby think tank The Century Foundation, which estimates that overall these programs have pumped $800 billion in the economy.) We’ll be getting a good read on whether all this relief did suppress employment now that CARES aid ended for some 7.5 million Americans earlier this month. But as Yahoo Finance’s Denitsa Tsekova reportedhereandhere, states that ended federal aid programs early didn’t see big increases in employment. That may mean these payments really weren’t enough to live off, or not enough to live off by themselves, which speaks to men looking to a combination of sources, like under the table income or family support and possibly some savings (see below).\n-Early retirement, pensions, disability and lawsuits\nAdmittedly, this is a bit of a hodgepodge. And as is the case with many of these categories, hard data is tough to come by, but it is the case that millions of men under 64 are at least partly living off of pensions and 401(k)s. This would include everything from C-suite executives to union members. And don’t forget municipal workers, who make up almost 14% of the U.S. workforce. According to the U.S. Census Bureau, there are some 6,000 public sector retirement systems in the U.S.Collectively these plans have $4.5 trillion in assets,with 14.7 million working members and 11.2 million retirees. The plans distribute $323 billion in benefits annually, and again, some to men who are younger than 64. In fact in almost two-thirds of these plans,if you started working at 25, you max out at 57, a real inducement to stop working — at least at that job of course.\nVolunteers load cars with turkeys and other food assistance for laid off Walt Disney World cast members and others at a food distribution event on December 12, 2020 in Orlando, Florida. (Photo by Paul Hennessy/NurPhoto via Getty Images)More\nThere’s also disability insurance from the Social Security Administration that is beingpaid to some 9 million Americanswhomay receive payments many years before retirement age. That's why I am including disability here, but not plain vanilla Social Security, which you can’t receive until age 62. The maximum disability benefit amount you can receive each month is currently $3,148. (However, the average beneficiary receives about $1,277 per month, according to the law group Social Security Disability Advocates.) Overall, it looks like theSSA pays out some $130 billion in disability annually.That’s not nothing. Then there’s money paid out in medical malpractice each year, smaller true, but stillestimated to be in excess of $3 billion.And don't forgetpayments from legal settlements and class action lawsuits.\nYou argue all day about the right or wrong when it comes to these payouts, but the fact is many of them didn’t exist, or not at this magnitude, decades ago.\n-Savings, trading stocks, and bitcoin\nConsider now men are living off savings, or from money made in the market or maybe even selling NFTs. How many is it exactly? Who knows, but quite a few for sure. First off, Americans on average do have some money in the bank. Savings as a percentage of disposable income,according to the Federal Reserve of Kansas City,hit a record high of 33% in the spring of 2020 and is still at 14%, or nearly twice as high as it was prior to the pandemic.\nAnd according to arecent survey by Northwestern Mutual,average personal savings are up over 10% compared to last year, from $65,900 last year to $73,100. Average retirement savings increased 13%, from $87,500 last year to $98,800 today. So there’s that.\nNext let’s look at investing — first stocks. It is not irrelevant to this narrative that the S&P 500 has climbed from 2,480 on March 12, 2020 — the day after the World Health Organization declared COVID a pandemic— to 4,441 today, or almost 80%. That’s a huge gain. Much of the action of course has been retail investors and the meme stock boom, as millions of American males stuck at home with nothing to do all day for the past 18 months passed the time trading stocks. Credit Suisse estimates that since the beginning of 2020, “retail trading as a share of overall market activityhas nearly doubledfrom between 15% and 18% to over 30%,” as CNBC reported. How many men were doing this and supporting themselves? Unclear, but upstart trading platform Robinhood (HOOD) — the broker dealer of choice for many of these new investors — reported that it had22.5 million funded user accountslast month, up from 7.2 million in March of 2020. Let’s just say 15 million new accounts is quite a number.\nNow crypto. You can laugh all you want, but the simple fact is that theprice of bitcoinis up from $4,861 on March 12, 2000 to $47,763 today, or basically up 10X, (and remember it even hit $64,888.99 this spring). Back to Robinhood, which according to The New York Times, also reported last month that “revenue from cryptocurrency trading fees totaled $233 million, a nearly 50-fold jump from $5 million a year earlier.” (And those are just fees off the trades, mind you.) Bottom line: Folks have made money here. (Of course these guys should be paying taxes on all those stock and crypto gains.)\nRobinhood Markets, Inc. CEO and co-founder Vlad Tenev and co-founder Baiju Bhatt pose with Robinhood signage on Wall Street after the company's IPO in New York City, U.S., July 29, 2021. REUTERS/Andrew Kelly-Working for cash, aka the under-the-table economy\nThis one is very tough to measure, too.A study by the Federal Reserve of St. Louisestimates that the average size of the “informal economy” in developed countries is 13% of GDP. Honestly, that could be off by many percentage points, but just to give you a ballpark, GDP in the U.S. this year is about $22 trillion. So 13% of that is $2.86 trillion. As it turns out, $2 trillion-plus, is a number that has been thrown around quite a bit (hereandherefor instance) when it comes to estimating the size of the cash economy in the U.S. Even if half that money is paid out to women, that still leaves, say, $1 trillion dollars being made by men in this country off the books. That’s a big chunk of change. Are more people than ever working for cash these days? Again, another question that’s impossible to answer. I would bet it’s not fewer. For example, my electrician Luis just told me he can’t get anyone to work for him anymore — they all want to get paid in cash.\n-Living off family members\nJust to take one facet,the Pew Research Center reportedlast year that the pandemic “has pushed millions of Americans, especially young adults, to move in with family members. The share of 18- to 29-year-olds living with their parents has become a majority since U.S. coronavirus cases began spreading [in early 2020], surpassing the previous peak during the Great Depression era. In July, 52% of young adults resided with one or both of their parents, up from 47% in February.” How many of these individuals are males living rent free (and sharing food too), which maybe means they don’t have to work? Who knows, but some. Ditto for males who have moved in with in-laws or siblings. And again, many men are choosing to stay home and take care of kids while their spouses work.\n-Illegal work\nFront and center here is selling illegal drugs. Sadly, business looks to be booming, that is if overdoses are any sort of measure.According to the Washington Post, overdose deaths hit 93,000 last year, up a stunning 30% from 2019. Most of the overdoses were attributed to opioids; heroin, synthetic opioids like OxyContin and in particular Fentanyl. (This despite drug dealers facingsupply chain issuesduring COVID.) How many Americans are in this business and who are they? A number is almost impossible to come by here, but as for who they are,a government report on drug trafficking arrestsfrom five years ago notes that ”the majority of drug trafficking offenders were male (84.9%), the average age of these offenders at sentencing was 36 years, 70% were United States citizens (although this rate varied substantially depending on the type of drug involved), and that almost half (49.4%) of drug traffickers had little or no prior criminal history.” How big a business is selling drugs in America? Could beas much as $100 billion.I think it’s fair to say that a market that size requires many thousands of employees.\nWhat about other types of crime and criminals, everything from robbers and thieves to prostitutes and pimps? To that point there aresome 2 million people incarcerated in the U.S.right now. (We have the highest absolute number and the highest per capita on the planet, and holdsome 25% of the world's total prisoners, according to the ACLU.) Being in prison is another way of living in America without working, I guess. But not counting those locked up, how many bad guys are out there on the street? Conservatively, it has to be thousands and thousands, and speaking to this story, they're all doing their thing and not participating in the labor force.\nORLEANS, MASSACHUSETTS - JULY 10: A man holds onto a clamming rake while clamming at low tide July 10, 2021 in Town Cove, Orleans, Massachusetts. He filled a bushel basket of cherry stone clams. (Photo by Robert Nickelsberg/Getty Images)More-Living off the land\nThis would include gardening, fishing, hunting, clamming, berrying, and just general foraging. The numbers here seem to be climbing. Here for instancefrom The Guardian:\n“Fishing and huntinglicense sales increased 10%in California during the pandemic, reversing years of decline. Clamming has grown in popularity for several reasons: people are looking for safe activities to do outdoors, but also some are clamming for subsistence and trying to get money from selling the shellfish (which is illegal without a commercial license).”\nDitto for Washington state, according to The Spokesman-Review:\n“From the start of the 2020 licensing year in May through Dec. 31, WDFW [Washington Department of Fish and Wildlife] sold nearly 45,000 more fishing licenses and 12,000 more hunting licenses than 2019. The number of new license holders — defined as someone who hadn’t purchased one for the previous five years — went up 16% for fishing licenses and almost 40% for hunters.”\nAs for growing vegetables in home gardens, yes, it is up, way up too. Even before the pandemic, there were estimates thata third of American families grew vegetables.Now this,NPRreported last year:\n“‘We're being flooded with vegetable orders,’ says George Ball, executive chairman of the Burpee Seed Company, based in Warminster, Penn.\nBall says he has noticed spikes in seed sales during bad times: the stock market crash of 1987, the dot com bubble burst of 2000, and he remembers the two oil crises of the 1970s from his childhood. But he says he has not seen a spike this large and widespread.\nSo there you have it. It’s a whole range of ways and means, behaviors and experiences. I’m sure I missed some, too. Again, some non-working men are in dire straits and need our help. Others are living non-working lives without burdening society or others, such as a fireman on early retirement (though some argue municipal employee pensions are too high), or an investor who made a ton of money in the market and called it quits, or maybe a wilderness guy living off the land in Alaska.\nAnd some non-working men are not playing fair. Like getting paid under the table, fudging insurance claims or social programs. Some freeload off relatives. And some engage in overtly illegal behavior like boosting branded goods from chain stores to sell online or dealing heroin.\nI would imagine that more than a few of these men create a portfolio of sources, though I’m not sure they really think of it that way. Take for example a hypothetical guy in a rural area who lives with his grandmother rent free, (he does help her with the garden some). This guy also does some cash carpentry work, hunts for game, gets some food off his ex-wife’s WIC and helps his brother sell some weed. Can you get by this way? Some men probably are. Is this the new American way? For some men it probably is.\nThat example perhaps, and to be sure of all of the above, I think go a long way toward explaining that chart from the beginning of the story, the one that shows the labor participation rate falling off a cliff over the past seven decades. And speaking of charts, another striking one came to mind when I was writing this, which I put here below. It shows U.S. GDP over the same time period as the labor participation rate.\nChart of the U.S. Gross Domestic Product over time, courtesy of the St. Louis Federal Reserve\nOf course, the line on this GDP chart is inversely correlated with the line on the labor participation graph. And I think there is a relationship between the two. Which is to say, the wealthier our nation has become over the decades, the less men are working. Fact is there is just a ton of money sloshing around in our country. And men seem to be able to get their hands on it, whether obtained legally, borrowed, leached off of or stolen.\nIt seems like working legally to provide for yourself in America is really just one option these days.\nThis article was featured in a Saturday edition of the Morning Brief on September 18, 2021. Get the Morning Brief sent directly to your inbox every Monday to Friday by 6:30 a.m. ET.Subscribe\nAndy Serwer is editor-in-chief of Yahoo Finance. Follow him on Twitter:@serwer","news_type":1},"isVote":1,"tweetType":1,"viewCount":197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860729860,"gmtCreate":1632216291350,"gmtModify":1632802019601,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"Fund House Are The One Who Can Move And Make The Market.","listText":"Fund House Are The One Who Can Move And Make The Market.","text":"Fund House Are The One Who Can Move And Make The Market.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860729860","repostId":"1198860415","repostType":4,"isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":855702498,"gmtCreate":1635397167980,"gmtModify":1635397168121,"author":{"id":"3581689230768222","authorId":"3581689230768222","name":"TW_GPS_D","avatar":"https://static.tigerbbs.com/73bbe1ac5cfa510623ac57658826d8ec","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581689230768222","idStr":"3581689230768222"},"themes":[],"htmlText":"Willing Buyer, Willing Seller.&nbsp;They Both Will Think They Got A Good Deal.&nbsp;But Only&nbsp;Their Result Will Tell.&nbsp;","listText":"Willing Buyer, Willing Seller.&nbsp;They Both Will Think They Got A Good Deal.&nbsp;But Only&nbsp;Their Result Will Tell.&nbsp;","text":"Willing Buyer, Willing Seller. They Both Will Think They Got A Good Deal. But Only Their Result Will Tell.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/855702498","repostId":"2178323712","repostType":4,"isVote":1,"tweetType":1,"viewCount":805,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}